﻿<?xml version="1.0" encoding="utf-8"?>
<Return xmlns="http://www.irs.gov/efile" xsi:schemaLocation="http://www.irs.gov/efile" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" returnVersion="2017v2.3">
  <ReturnHeader binaryAttachmentCnt="0">
    <ReturnTs>2018-09-27T13:26:02-05:00</ReturnTs>
    <TaxPeriodEndDt>2017-12-31</TaxPeriodEndDt>
    <PreparerFirmGrp>
      <PreparerFirmName>
        <BusinessNameLine1Txt>WITHUMSMITHBROWNPC</BusinessNameLine1Txt>
      </PreparerFirmName>
      <PreparerUSAddress>
        <AddressLine1Txt>4600 EAST WEST HWY 900</AddressLine1Txt>
        <CityNm>BETHESDA</CityNm>
        <StateAbbreviationCd>MD</StateAbbreviationCd>
        <ZIPCd>208143423</ZIPCd>
      </PreparerUSAddress>
    </PreparerFirmGrp>
    <ReturnTypeCd>990</ReturnTypeCd>
    <TaxPeriodBeginDt>2017-01-01</TaxPeriodBeginDt>
    <Filer>
      <EIN>042531031</EIN>
      <BusinessName>
        <BusinessNameLine1Txt>NATIONAL FOUNDATION FOR CANCER RESEARCH</BusinessNameLine1Txt>
      </BusinessName>
      <InCareOfNm>% SUJUAN BA</InCareOfNm>
      <BusinessNameControlTxt>NATI</BusinessNameControlTxt>
      <PhoneNum>3016541250</PhoneNum>
      <USAddress>
        <AddressLine1Txt>5515 SECURITY LANE Suite 1105</AddressLine1Txt>
        <CityNm>ROCKVILLE</CityNm>
        <StateAbbreviationCd>MD</StateAbbreviationCd>
        <ZIPCd>20852</ZIPCd>
      </USAddress>
    </Filer>
    <BusinessOfficerGrp>
      <PersonNm>FRANKLIN C SALISBURY JR</PersonNm>
      <PersonTitleTxt>CEO</PersonTitleTxt>
      <PhoneNum>3016541250</PhoneNum>
      <SignatureDt>2018-09-26</SignatureDt>
      <DiscussWithPaidPreparerInd>true</DiscussWithPaidPreparerInd>
    </BusinessOfficerGrp>
    <PreparerPersonGrp>
      <PreparerPersonNm>RICHARD L RUVELSON</PreparerPersonNm>
      <PTIN>P00234075</PTIN>
      <PhoneNum>3012726000</PhoneNum>
    </PreparerPersonGrp>
    <TaxYr>2017</TaxYr>
    <BuildTS>2022-09-23 18:48:47Z</BuildTS>
  </ReturnHeader>
  <ReturnData documentCnt="11">
    <IRS990 documentId="IRS990" referenceDocumentId="IRS990ScheduleO">
      <AddressChangeInd>X</AddressChangeInd>
      <PrincipalOfficerNm>FRANKLIN C SALISBURY JR</PrincipalOfficerNm>
      <USAddress>
        <AddressLine1Txt>5515 SECURITY LANE SUITE 1105</AddressLine1Txt>
        <CityNm>ROCKVILLE</CityNm>
        <StateAbbreviationCd>MD</StateAbbreviationCd>
        <ZIPCd>20852</ZIPCd>
      </USAddress>
      <GrossReceiptsAmt>15205359</GrossReceiptsAmt>
      <GroupReturnForAffiliatesInd>false</GroupReturnForAffiliatesInd>
      <GroupExemptionNum>5582</GroupExemptionNum>
      <Organization501c3Ind>X</Organization501c3Ind>
      <WebsiteAddressTxt>WWW.NFCR.ORG</WebsiteAddressTxt>
      <TypeOfOrganizationCorpInd>X</TypeOfOrganizationCorpInd>
      <FormationYr>1973</FormationYr>
      <LegalDomicileStateCd>MA</LegalDomicileStateCd>
      <ActivityOrMissionDesc>TO SUPPORT CANCER RESEARCH AND PUBLIC EDUCATION RELATING TO PREVENTION, EARLIER DIAGNOSIS, BETTER TREATMENTS AND ULTIMATELY, A CURE FOR CANCER.</ActivityOrMissionDesc>
      <VotingMembersGoverningBodyCnt>6</VotingMembersGoverningBodyCnt>
      <VotingMembersIndependentCnt>6</VotingMembersIndependentCnt>
      <TotalEmployeeCnt>30</TotalEmployeeCnt>
      <TotalVolunteersCnt>100</TotalVolunteersCnt>
      <TotalGrossUBIAmt>11802</TotalGrossUBIAmt>
      <NetUnrelatedBusTxblIncmAmt>10424</NetUnrelatedBusTxblIncmAmt>
      <PYContributionsGrantsAmt>13952247</PYContributionsGrantsAmt>
      <CYContributionsGrantsAmt>11921451</CYContributionsGrantsAmt>
      <PYProgramServiceRevenueAmt>0</PYProgramServiceRevenueAmt>
      <CYProgramServiceRevenueAmt>0</CYProgramServiceRevenueAmt>
      <PYInvestmentIncomeAmt>364941</PYInvestmentIncomeAmt>
      <CYInvestmentIncomeAmt>740805</CYInvestmentIncomeAmt>
      <PYOtherRevenueAmt>346806</PYOtherRevenueAmt>
      <CYOtherRevenueAmt>296389</CYOtherRevenueAmt>
      <PYTotalRevenueAmt>14663994</PYTotalRevenueAmt>
      <CYTotalRevenueAmt>12958645</CYTotalRevenueAmt>
      <PYGrantsAndSimilarPaidAmt>3164316</PYGrantsAndSimilarPaidAmt>
      <CYGrantsAndSimilarPaidAmt>2704783</CYGrantsAndSimilarPaidAmt>
      <PYBenefitsPaidToMembersAmt>0</PYBenefitsPaidToMembersAmt>
      <CYBenefitsPaidToMembersAmt>0</CYBenefitsPaidToMembersAmt>
      <PYSalariesCompEmpBnftPaidAmt>2340557</PYSalariesCompEmpBnftPaidAmt>
      <CYSalariesCompEmpBnftPaidAmt>2584611</CYSalariesCompEmpBnftPaidAmt>
      <PYTotalProfFndrsngExpnsAmt>45692</PYTotalProfFndrsngExpnsAmt>
      <CYTotalProfFndrsngExpnsAmt>50237</CYTotalProfFndrsngExpnsAmt>
      <CYTotalFundraisingExpenseAmt>2686041</CYTotalFundraisingExpenseAmt>
      <PYOtherExpensesAmt>7615468</PYOtherExpensesAmt>
      <CYOtherExpensesAmt>8092769</CYOtherExpensesAmt>
      <PYTotalExpensesAmt>13166033</PYTotalExpensesAmt>
      <CYTotalExpensesAmt>13432400</CYTotalExpensesAmt>
      <PYRevenuesLessExpensesAmt>1497961</PYRevenuesLessExpensesAmt>
      <CYRevenuesLessExpensesAmt>-473755</CYRevenuesLessExpensesAmt>
      <TotalAssetsBOYAmt>15027884</TotalAssetsBOYAmt>
      <TotalAssetsEOYAmt>14949937</TotalAssetsEOYAmt>
      <TotalLiabilitiesBOYAmt>2474411</TotalLiabilitiesBOYAmt>
      <TotalLiabilitiesEOYAmt>2043145</TotalLiabilitiesEOYAmt>
      <NetAssetsOrFundBalancesBOYAmt>12553473</NetAssetsOrFundBalancesBOYAmt>
      <NetAssetsOrFundBalancesEOYAmt>12906792</NetAssetsOrFundBalancesEOYAmt>
      <InfoInScheduleOPartIIIInd>X</InfoInScheduleOPartIIIInd>
      <MissionDesc>SEE SCHEDULE O</MissionDesc>
      <SignificantNewProgramSrvcInd>false</SignificantNewProgramSrvcInd>
      <SignificantChangeInd>false</SignificantChangeInd>
      <ExpenseAmt>4353838</ExpenseAmt>
      <GrantAmt>2704783</GrantAmt>
      <Desc>CANCER RESEARCH - SEE SCHEDULE O</Desc>
      <ProgSrvcAccomActy2Grp>
        <ExpenseAmt>5308606</ExpenseAmt>
        <Desc>CANCER PREVENTION EDUCATION TO THE PUBLIC - SEE SCHEDULE O</Desc>
      </ProgSrvcAccomActy2Grp>
      <TotalProgramServiceExpensesAmt>9662444</TotalProgramServiceExpensesAmt>
      <DescribedInSection501c3Ind referenceDocumentId="IRS990ScheduleA">true</DescribedInSection501c3Ind>
      <ScheduleBRequiredInd referenceDocumentId="IRS990ScheduleB">true</ScheduleBRequiredInd>
      <PoliticalCampaignActyInd>false</PoliticalCampaignActyInd>
      <LobbyingActivitiesInd>false</LobbyingActivitiesInd>
      <SubjectToProxyTaxInd>false</SubjectToProxyTaxInd>
      <DonorAdvisedFundInd referenceDocumentId="IRS990ScheduleD">true</DonorAdvisedFundInd>
      <ConservationEasementsInd referenceDocumentId="IRS990ScheduleD">false</ConservationEasementsInd>
      <CollectionsOfArtInd referenceDocumentId="IRS990ScheduleD">false</CollectionsOfArtInd>
      <CreditCounselingInd referenceDocumentId="IRS990ScheduleD">false</CreditCounselingInd>
      <TempOrPermanentEndowmentsInd referenceDocumentId="IRS990ScheduleD">true</TempOrPermanentEndowmentsInd>
      <ReportLandBuildingEquipmentInd referenceDocumentId="IRS990ScheduleD">true</ReportLandBuildingEquipmentInd>
      <ReportInvestmentsOtherSecInd referenceDocumentId="IRS990ScheduleD">false</ReportInvestmentsOtherSecInd>
      <ReportProgramRelatedInvstInd referenceDocumentId="IRS990ScheduleD">false</ReportProgramRelatedInvstInd>
      <ReportOtherAssetsInd referenceDocumentId="IRS990ScheduleD">true</ReportOtherAssetsInd>
      <ReportOtherLiabilitiesInd referenceDocumentId="IRS990ScheduleD">false</ReportOtherLiabilitiesInd>
      <IncludeFIN48FootnoteInd referenceDocumentId="IRS990ScheduleD">true</IncludeFIN48FootnoteInd>
      <IndependentAuditFinclStmtInd referenceDocumentId="IRS990ScheduleD">false</IndependentAuditFinclStmtInd>
      <ConsolidatedAuditFinclStmtInd referenceDocumentId="IRS990ScheduleD">true</ConsolidatedAuditFinclStmtInd>
      <SchoolOperatingInd>false</SchoolOperatingInd>
      <ForeignOfficeInd>false</ForeignOfficeInd>
      <ForeignActivitiesInd referenceDocumentId="IRS990ScheduleF">true</ForeignActivitiesInd>
      <MoreThan5000KToOrgInd referenceDocumentId="IRS990ScheduleF">false</MoreThan5000KToOrgInd>
      <MoreThan5000KToIndividualsInd referenceDocumentId="IRS990ScheduleF">true</MoreThan5000KToIndividualsInd>
      <ProfessionalFundraisingInd referenceDocumentId="IRS990ScheduleG">true</ProfessionalFundraisingInd>
      <FundraisingActivitiesInd referenceDocumentId="IRS990ScheduleG">true</FundraisingActivitiesInd>
      <GamingActivitiesInd referenceDocumentId="IRS990ScheduleG">false</GamingActivitiesInd>
      <OperateHospitalInd>false</OperateHospitalInd>
      <GrantsToOrganizationsInd referenceDocumentId="IRS990ScheduleI">true</GrantsToOrganizationsInd>
      <GrantsToIndividualsInd referenceDocumentId="IRS990ScheduleI">true</GrantsToIndividualsInd>
      <ScheduleJRequiredInd referenceDocumentId="IRS990ScheduleJ">true</ScheduleJRequiredInd>
      <TaxExemptBondsInd>false</TaxExemptBondsInd>
      <EngagedInExcessBenefitTransInd>false</EngagedInExcessBenefitTransInd>
      <PYExcessBenefitTransInd>false</PYExcessBenefitTransInd>
      <LoanOutstandingInd>false</LoanOutstandingInd>
      <GrantToRelatedPersonInd>false</GrantToRelatedPersonInd>
      <BusinessRlnWithOrgMemInd>false</BusinessRlnWithOrgMemInd>
      <BusinessRlnWithFamMemInd>false</BusinessRlnWithFamMemInd>
      <BusinessRlnWithOfficerEntInd>false</BusinessRlnWithOfficerEntInd>
      <DeductibleNonCashContriInd referenceDocumentId="IRS990ScheduleM">true</DeductibleNonCashContriInd>
      <DeductibleArtContributionInd referenceDocumentId="IRS990ScheduleM">false</DeductibleArtContributionInd>
      <TerminateOperationsInd>false</TerminateOperationsInd>
      <PartialLiquidationInd>false</PartialLiquidationInd>
      <DisregardedEntityInd referenceDocumentId="IRS990ScheduleR">false</DisregardedEntityInd>
      <RelatedEntityInd referenceDocumentId="IRS990ScheduleR">true</RelatedEntityInd>
      <RelatedOrganizationCtrlEntInd>false</RelatedOrganizationCtrlEntInd>
      <TrnsfrExmptNonChrtblRltdOrgInd referenceDocumentId="IRS990ScheduleR">false</TrnsfrExmptNonChrtblRltdOrgInd>
      <ActivitiesConductedPrtshpInd referenceDocumentId="IRS990ScheduleR">false</ActivitiesConductedPrtshpInd>
      <ScheduleORequiredInd>true</ScheduleORequiredInd>
      <IRPDocumentCnt>28</IRPDocumentCnt>
      <IRPDocumentW2GCnt>0</IRPDocumentW2GCnt>
      <BackupWthldComplianceInd>true</BackupWthldComplianceInd>
      <EmployeeCnt>30</EmployeeCnt>
      <EmploymentTaxReturnsFiledInd>true</EmploymentTaxReturnsFiledInd>
      <UnrelatedBusIncmOverLimitInd>true</UnrelatedBusIncmOverLimitInd>
      <Form990TFiledInd>true</Form990TFiledInd>
      <ForeignFinancialAccountInd>true</ForeignFinancialAccountInd>
      <ForeignCountryCd>HK</ForeignCountryCd>
      <ProhibitedTaxShelterTransInd>false</ProhibitedTaxShelterTransInd>
      <TaxablePartyNotificationInd>false</TaxablePartyNotificationInd>
      <NondeductibleContributionsInd>false</NondeductibleContributionsInd>
      <QuidProQuoContributionsInd>true</QuidProQuoContributionsInd>
      <QuidProQuoContriDisclInd>true</QuidProQuoContriDisclInd>
      <Form8282PropertyDisposedOfInd>false</Form8282PropertyDisposedOfInd>
      <RcvFndsToPayPrsnlBnftCntrctInd>false</RcvFndsToPayPrsnlBnftCntrctInd>
      <PayPremiumsPrsnlBnftCntrctInd>false</PayPremiumsPrsnlBnftCntrctInd>
      <DAFExcessBusinessHoldingsInd>false</DAFExcessBusinessHoldingsInd>
      <TaxableDistributionsInd>false</TaxableDistributionsInd>
      <DistributionToDonorInd>false</DistributionToDonorInd>
      <IndoorTanningServicesInd>false</IndoorTanningServicesInd>
      <InfoInScheduleOPartVIInd>X</InfoInScheduleOPartVIInd>
      <GoverningBodyVotingMembersCnt>6</GoverningBodyVotingMembersCnt>
      <IndependentVotingMemberCnt>6</IndependentVotingMemberCnt>
      <FamilyOrBusinessRlnInd>true</FamilyOrBusinessRlnInd>
      <DelegationOfMgmtDutiesInd>false</DelegationOfMgmtDutiesInd>
      <ChangeToOrgDocumentsInd>true</ChangeToOrgDocumentsInd>
      <MaterialDiversionOrMisuseInd>false</MaterialDiversionOrMisuseInd>
      <MembersOrStockholdersInd>false</MembersOrStockholdersInd>
      <ElectionOfBoardMembersInd>false</ElectionOfBoardMembersInd>
      <DecisionsSubjectToApprovaInd>false</DecisionsSubjectToApprovaInd>
      <MinutesOfGoverningBodyInd>true</MinutesOfGoverningBodyInd>
      <MinutesOfCommitteesInd>true</MinutesOfCommitteesInd>
      <OfficerMailingAddressInd>false</OfficerMailingAddressInd>
      <LocalChaptersInd>true</LocalChaptersInd>
      <PoliciesReferenceChaptersInd>true</PoliciesReferenceChaptersInd>
      <Form990ProvidedToGvrnBodyInd>true</Form990ProvidedToGvrnBodyInd>
      <ConflictOfInterestPolicyInd>true</ConflictOfInterestPolicyInd>
      <AnnualDisclosureCoveredPrsnInd>true</AnnualDisclosureCoveredPrsnInd>
      <RegularMonitoringEnfrcInd>true</RegularMonitoringEnfrcInd>
      <WhistleblowerPolicyInd>true</WhistleblowerPolicyInd>
      <DocumentRetentionPolicyInd>true</DocumentRetentionPolicyInd>
      <CompensationProcessCEOInd>true</CompensationProcessCEOInd>
      <CompensationProcessOtherInd>true</CompensationProcessOtherInd>
      <InvestmentInJointVentureInd>false</InvestmentInJointVentureInd>
      <StatesWhereCopyOfReturnIsFldCd>AL</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>AK</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>AZ</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>AR</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>CA</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>CO</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>CT</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>DC</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>FL</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>GA</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>HI</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>IL</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>IN</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>KS</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>KY</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>ME</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>MD</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>MA</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>MI</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>MN</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>MS</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>NH</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>NJ</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>NM</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>NY</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>NC</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>ND</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>OH</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>OK</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>OR</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>PA</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>RI</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>SC</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>TN</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>UT</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>VA</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>WA</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>WV</StatesWhereCopyOfReturnIsFldCd>
      <StatesWhereCopyOfReturnIsFldCd>WI</StatesWhereCopyOfReturnIsFldCd>
      <OwnWebsiteInd>X</OwnWebsiteInd>
      <UponRequestInd>X</UponRequestInd>
      <BooksInCareOfDetail>
        <PersonNm>SUJUAN BA</PersonNm>
        <PhoneNum>3016541250</PhoneNum>
        <USAddress>
          <AddressLine1Txt>5515 SECURITY LANE SUITE 1105</AddressLine1Txt>
          <CityNm>ROCKVILLE</CityNm>
          <StateAbbreviationCd>MD</StateAbbreviationCd>
          <ZIPCd>20852</ZIPCd>
        </USAddress>
      </BooksInCareOfDetail>
      <InfoInScheduleOPartVIIInd>X</InfoInScheduleOPartVIIInd>
      <Form990PartVIISectionAGrp>
        <PersonNm>JOSEPH F FRANLIN</PersonNm>
        <TitleTxt>CHAIR</TitleTxt>
        <AverageHoursPerWeekRt>5.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0.0</AverageHoursPerWeekRltdOrgRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <OfficerInd>X</OfficerInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>WENDI P DENNARD</PersonNm>
        <TitleTxt>TREASURER</TitleTxt>
        <AverageHoursPerWeekRt>2.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0.0</AverageHoursPerWeekRltdOrgRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <OfficerInd>X</OfficerInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>MARK R BARAN</PersonNm>
        <TitleTxt>DIRECTOR (THRU 05/2017)</TitleTxt>
        <AverageHoursPerWeekRt>2.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0.0</AverageHoursPerWeekRltdOrgRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>JUDITH P BARNHARD</PersonNm>
        <TitleTxt>DIRECTOR</TitleTxt>
        <AverageHoursPerWeekRt>2.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0.0</AverageHoursPerWeekRltdOrgRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>MICHAEL BURKE</PersonNm>
        <TitleTxt>DIRECTOR</TitleTxt>
        <AverageHoursPerWeekRt>2.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0.0</AverageHoursPerWeekRltdOrgRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>PADMAKUMAR KAIMAL</PersonNm>
        <TitleTxt>DIRECTOR</TitleTxt>
        <AverageHoursPerWeekRt>2.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0.0</AverageHoursPerWeekRltdOrgRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>EDWARD S WEST</PersonNm>
        <TitleTxt>DIRECTOR</TitleTxt>
        <AverageHoursPerWeekRt>2.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0.0</AverageHoursPerWeekRltdOrgRt>
        <IndividualTrusteeOrDirectorInd>X</IndividualTrusteeOrDirectorInd>
        <ReportableCompFromOrgAmt>0</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>0</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>FRANKLIN C SALISBURY JR</PersonNm>
        <TitleTxt>CHIEF EXECUTIVE OFFICER</TitleTxt>
        <AverageHoursPerWeekRt>40.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>2.0</AverageHoursPerWeekRltdOrgRt>
        <OfficerInd>X</OfficerInd>
        <ReportableCompFromOrgAmt>312030</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>75872</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>SUJUAN BA</PersonNm>
        <TitleTxt>PRESIDENT/ COO</TitleTxt>
        <AverageHoursPerWeekRt>40.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>2.0</AverageHoursPerWeekRltdOrgRt>
        <OfficerInd>X</OfficerInd>
        <ReportableCompFromOrgAmt>311053</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>65163</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>KWOK LEUNG</PersonNm>
        <TitleTxt>CFO/SECRETARY</TitleTxt>
        <AverageHoursPerWeekRt>40.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>5.0</AverageHoursPerWeekRltdOrgRt>
        <OfficerInd>X</OfficerInd>
        <ReportableCompFromOrgAmt>182330</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>26896</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>YI WANG</PersonNm>
        <TitleTxt>CHIEF STRTGY OFF. - ALLIANCES</TitleTxt>
        <AverageHoursPerWeekRt>40.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>1.0</AverageHoursPerWeekRltdOrgRt>
        <HighestCompensatedEmployeeInd>X</HighestCompensatedEmployeeInd>
        <ReportableCompFromOrgAmt>195739</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>32183</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <Form990PartVIISectionAGrp>
        <PersonNm>JOSEPH M GILLMER</PersonNm>
        <TitleTxt>FRMR VP DVLPMNT (THRU 11/2017)</TitleTxt>
        <AverageHoursPerWeekRt>40.0</AverageHoursPerWeekRt>
        <AverageHoursPerWeekRltdOrgRt>0.0</AverageHoursPerWeekRltdOrgRt>
        <HighestCompensatedEmployeeInd>X</HighestCompensatedEmployeeInd>
        <ReportableCompFromOrgAmt>165065</ReportableCompFromOrgAmt>
        <ReportableCompFromRltdOrgAmt>0</ReportableCompFromRltdOrgAmt>
        <OtherCompensationAmt>19007</OtherCompensationAmt>
      </Form990PartVIISectionAGrp>
      <TotalReportableCompFromOrgAmt>1166217</TotalReportableCompFromOrgAmt>
      <TotReportableCompRltdOrgAmt>0</TotReportableCompRltdOrgAmt>
      <TotalOtherCompensationAmt>219121</TotalOtherCompensationAmt>
      <IndivRcvdGreaterThan100KCnt>5</IndivRcvdGreaterThan100KCnt>
      <FormerOfcrEmployeesListedInd>false</FormerOfcrEmployeesListedInd>
      <TotalCompGreaterThan150KInd>true</TotalCompGreaterThan150KInd>
      <CompensationFromOtherSrcsInd>false</CompensationFromOtherSrcsInd>
      <ContractorCompensationGrp>
        <ContractorName>
          <PersonNm>REDFIELD DIRECT LLC</PersonNm>
        </ContractorName>
        <ContractorAddress>
          <USAddress>
            <AddressLine1Txt>1901 HOWARD STREET</AddressLine1Txt>
            <CityNm>OMAHA</CityNm>
            <StateAbbreviationCd>NE</StateAbbreviationCd>
            <ZIPCd>68102</ZIPCd>
          </USAddress>
        </ContractorAddress>
        <ServicesDesc>LABEL PRINTING</ServicesDesc>
        <CompensationAmt>893001</CompensationAmt>
      </ContractorCompensationGrp>
      <ContractorCompensationGrp>
        <ContractorName>
          <PersonNm>CALMARK GROUP LLC</PersonNm>
        </ContractorName>
        <ContractorAddress>
          <USAddress>
            <AddressLine1Txt>6755 S SAYRE AVE</AddressLine1Txt>
            <CityNm>BEDFORD PARK</CityNm>
            <StateAbbreviationCd>IL</StateAbbreviationCd>
            <ZIPCd>60638</ZIPCd>
          </USAddress>
        </ContractorAddress>
        <ServicesDesc>MAILSHOP</ServicesDesc>
        <CompensationAmt>775437</CompensationAmt>
      </ContractorCompensationGrp>
      <ContractorCompensationGrp>
        <ContractorName>
          <PersonNm>CP DIRECT INC</PersonNm>
        </ContractorName>
        <ContractorAddress>
          <USAddress>
            <AddressLine1Txt>4600 A BOSTON WAY</AddressLine1Txt>
            <CityNm>LANHAM</CityNm>
            <StateAbbreviationCd>MD</StateAbbreviationCd>
            <ZIPCd>20706</ZIPCd>
          </USAddress>
        </ContractorAddress>
        <ServicesDesc>PRINTING</ServicesDesc>
        <CompensationAmt>510397</CompensationAmt>
      </ContractorCompensationGrp>
      <ContractorCompensationGrp>
        <ContractorName>
          <PersonNm>KEY ACQUISITION PARTNERS</PersonNm>
        </ContractorName>
        <ContractorAddress>
          <USAddress>
            <AddressLine1Txt>2525 RIVA ROAD STE 145</AddressLine1Txt>
            <CityNm>ANNAPOLIS</CityNm>
            <StateAbbreviationCd>MD</StateAbbreviationCd>
            <ZIPCd>21401</ZIPCd>
          </USAddress>
        </ContractorAddress>
        <ServicesDesc>LIST BROKER</ServicesDesc>
        <CompensationAmt>430385</CompensationAmt>
      </ContractorCompensationGrp>
      <ContractorCompensationGrp>
        <ContractorName>
          <PersonNm>MACKAY MITCHELL ENVELOPE CO</PersonNm>
        </ContractorName>
        <ContractorAddress>
          <USAddress>
            <AddressLine1Txt>2100 ELM ST SE</AddressLine1Txt>
            <CityNm>MINNEAPOLIS</CityNm>
            <StateAbbreviationCd>MN</StateAbbreviationCd>
            <ZIPCd>55414</ZIPCd>
          </USAddress>
        </ContractorAddress>
        <ServicesDesc>ENVELOPE PRINTING</ServicesDesc>
        <CompensationAmt>425123</CompensationAmt>
      </ContractorCompensationGrp>
      <CntrctRcvdGreaterThan100KCnt>8</CntrctRcvdGreaterThan100KCnt>
      <InfoInScheduleOPartVIIIInd>X</InfoInScheduleOPartVIIIInd>
      <FederatedCampaignsAmt>67697</FederatedCampaignsAmt>
      <FundraisingAmt>347762</FundraisingAmt>
      <AllOtherContributionsAmt>11505992</AllOtherContributionsAmt>
      <NoncashContributionsAmt>236189</NoncashContributionsAmt>
      <TotalContributionsAmt>11921451</TotalContributionsAmt>
      <TotalProgramServiceRevenueAmt>0</TotalProgramServiceRevenueAmt>
      <InvestmentIncomeGrp>
        <TotalRevenueColumnAmt>285338</TotalRevenueColumnAmt>
        <ExclusionAmt>285338</ExclusionAmt>
      </InvestmentIncomeGrp>
      <IncmFromInvestBondProceedsGrp>
        <TotalRevenueColumnAmt>0</TotalRevenueColumnAmt>
      </IncmFromInvestBondProceedsGrp>
      <RoyaltiesRevenueGrp>
        <TotalRevenueColumnAmt>11224</TotalRevenueColumnAmt>
        <ExclusionAmt>11224</ExclusionAmt>
      </RoyaltiesRevenueGrp>
      <RentalIncomeOrLossGrp>
        <RealAmt>0</RealAmt>
        <PersonalAmt>0</PersonalAmt>
      </RentalIncomeOrLossGrp>
      <NetRentalIncomeOrLossGrp>
        <TotalRevenueColumnAmt>0</TotalRevenueColumnAmt>
      </NetRentalIncomeOrLossGrp>
      <GrossAmountSalesAssetsGrp>
        <SecuritiesAmt>2653324</SecuritiesAmt>
      </GrossAmountSalesAssetsGrp>
      <LessCostOthBasisSalesExpnssGrp>
        <SecuritiesAmt>2197857</SecuritiesAmt>
      </LessCostOthBasisSalesExpnssGrp>
      <GainOrLossGrp>
        <SecuritiesAmt>455467</SecuritiesAmt>
      </GainOrLossGrp>
      <NetGainOrLossInvestmentsGrp>
        <TotalRevenueColumnAmt>455467</TotalRevenueColumnAmt>
        <ExclusionAmt>455467</ExclusionAmt>
      </NetGainOrLossInvestmentsGrp>
      <FundraisingGrossIncomeAmt>37702</FundraisingGrossIncomeAmt>
      <ContriRptFundraisingEventAmt>347762</ContriRptFundraisingEventAmt>
      <FundraisingDirectExpensesAmt>48857</FundraisingDirectExpensesAmt>
      <NetIncmFromFundraisingEvtGrp>
        <TotalRevenueColumnAmt>-11155</TotalRevenueColumnAmt>
        <ExclusionAmt>-11155</ExclusionAmt>
      </NetIncmFromFundraisingEvtGrp>
      <GamingGrossIncomeAmt>0</GamingGrossIncomeAmt>
      <GamingDirectExpensesAmt>0</GamingDirectExpensesAmt>
      <NetIncomeFromGamingGrp>
        <TotalRevenueColumnAmt>0</TotalRevenueColumnAmt>
      </NetIncomeFromGamingGrp>
      <GrossSalesOfInventoryAmt>0</GrossSalesOfInventoryAmt>
      <CostOfGoodsSoldAmt>0</CostOfGoodsSoldAmt>
      <NetIncomeOrLossGrp>
        <TotalRevenueColumnAmt>0</TotalRevenueColumnAmt>
      </NetIncomeOrLossGrp>
      <OtherRevenueMiscGrp>
        <Desc>MAILING LIST RENTALS</Desc>
        <BusinessCd>541800</BusinessCd>
        <TotalRevenueColumnAmt>296320</TotalRevenueColumnAmt>
        <UnrelatedBusinessRevenueAmt>11802</UnrelatedBusinessRevenueAmt>
        <ExclusionAmt>284518</ExclusionAmt>
      </OtherRevenueMiscGrp>
      <OtherRevenueTotalAmt>296320</OtherRevenueTotalAmt>
      <TotalRevenueGrp>
        <TotalRevenueColumnAmt>12958645</TotalRevenueColumnAmt>
        <UnrelatedBusinessRevenueAmt>11802</UnrelatedBusinessRevenueAmt>
        <ExclusionAmt>1025392</ExclusionAmt>
      </TotalRevenueGrp>
      <GrantsToDomesticOrgsGrp>
        <TotalAmt>2504042</TotalAmt>
        <ProgramServicesAmt>2504042</ProgramServicesAmt>
      </GrantsToDomesticOrgsGrp>
      <GrantsToDomesticIndividualsGrp>
        <TotalAmt>160741</TotalAmt>
        <ProgramServicesAmt>160741</ProgramServicesAmt>
      </GrantsToDomesticIndividualsGrp>
      <ForeignGrantsGrp>
        <TotalAmt>40000</TotalAmt>
        <ProgramServicesAmt>40000</ProgramServicesAmt>
      </ForeignGrantsGrp>
      <BenefitsToMembersGrp>
        <TotalAmt>0</TotalAmt>
      </BenefitsToMembersGrp>
      <CompCurrentOfcrDirectorsGrp>
        <TotalAmt>962221</TotalAmt>
        <ProgramServicesAmt>777899</ProgramServicesAmt>
        <ManagementAndGeneralAmt>176792</ManagementAndGeneralAmt>
        <FundraisingAmt>7530</FundraisingAmt>
      </CompCurrentOfcrDirectorsGrp>
      <CompDisqualPersonsGrp>
        <TotalAmt>0</TotalAmt>
      </CompDisqualPersonsGrp>
      <OtherSalariesAndWagesGrp>
        <TotalAmt>1266903</TotalAmt>
        <ProgramServicesAmt>879734</ProgramServicesAmt>
        <ManagementAndGeneralAmt>181406</ManagementAndGeneralAmt>
        <FundraisingAmt>205763</FundraisingAmt>
      </OtherSalariesAndWagesGrp>
      <PensionPlanContributionsGrp>
        <TotalAmt>123315</TotalAmt>
        <ProgramServicesAmt>78520</ProgramServicesAmt>
        <ManagementAndGeneralAmt>19927</ManagementAndGeneralAmt>
        <FundraisingAmt>24868</FundraisingAmt>
      </PensionPlanContributionsGrp>
      <OtherEmployeeBenefitsGrp>
        <TotalAmt>97504</TotalAmt>
        <ProgramServicesAmt>67331</ProgramServicesAmt>
        <ManagementAndGeneralAmt>17754</ManagementAndGeneralAmt>
        <FundraisingAmt>12419</FundraisingAmt>
      </OtherEmployeeBenefitsGrp>
      <PayrollTaxesGrp>
        <TotalAmt>134668</TotalAmt>
        <ProgramServicesAmt>99218</ProgramServicesAmt>
        <ManagementAndGeneralAmt>21700</ManagementAndGeneralAmt>
        <FundraisingAmt>13750</FundraisingAmt>
      </PayrollTaxesGrp>
      <FeesForServicesManagementGrp>
        <TotalAmt>0</TotalAmt>
      </FeesForServicesManagementGrp>
      <FeesForServicesLegalGrp>
        <TotalAmt>140391</TotalAmt>
        <ProgramServicesAmt>40951</ProgramServicesAmt>
        <ManagementAndGeneralAmt>99440</ManagementAndGeneralAmt>
      </FeesForServicesLegalGrp>
      <FeesForServicesAccountingGrp>
        <TotalAmt>41110</TotalAmt>
        <ManagementAndGeneralAmt>41110</ManagementAndGeneralAmt>
      </FeesForServicesAccountingGrp>
      <FeesForServicesLobbyingGrp>
        <TotalAmt>0</TotalAmt>
      </FeesForServicesLobbyingGrp>
      <FeesForServicesProfFundraising>
        <TotalAmt>50237</TotalAmt>
        <FundraisingAmt>50237</FundraisingAmt>
      </FeesForServicesProfFundraising>
      <FeesForSrvcInvstMgmntFeesGrp>
        <TotalAmt>64774</TotalAmt>
        <ManagementAndGeneralAmt>64774</ManagementAndGeneralAmt>
      </FeesForSrvcInvstMgmntFeesGrp>
      <FeesForServicesOtherGrp>
        <TotalAmt>269918</TotalAmt>
        <ProgramServicesAmt>168865</ProgramServicesAmt>
        <ManagementAndGeneralAmt>97868</ManagementAndGeneralAmt>
        <FundraisingAmt>3185</FundraisingAmt>
      </FeesForServicesOtherGrp>
      <AdvertisingGrp>
        <TotalAmt>47377</TotalAmt>
        <ManagementAndGeneralAmt>47377</ManagementAndGeneralAmt>
      </AdvertisingGrp>
      <OfficeExpensesGrp>
        <TotalAmt>273571</TotalAmt>
        <ProgramServicesAmt>67124</ProgramServicesAmt>
        <ManagementAndGeneralAmt>196515</ManagementAndGeneralAmt>
        <FundraisingAmt>9932</FundraisingAmt>
      </OfficeExpensesGrp>
      <InformationTechnologyGrp>
        <TotalAmt>434414</TotalAmt>
        <ProgramServicesAmt>304642</ProgramServicesAmt>
        <ManagementAndGeneralAmt>2936</ManagementAndGeneralAmt>
        <FundraisingAmt>126836</FundraisingAmt>
      </InformationTechnologyGrp>
      <RoyaltiesGrp>
        <TotalAmt>0</TotalAmt>
      </RoyaltiesGrp>
      <OccupancyGrp>
        <TotalAmt>200210</TotalAmt>
        <ProgramServicesAmt>147883</ProgramServicesAmt>
        <ManagementAndGeneralAmt>31924</ManagementAndGeneralAmt>
        <FundraisingAmt>20403</FundraisingAmt>
      </OccupancyGrp>
      <TravelGrp>
        <TotalAmt>203205</TotalAmt>
        <ProgramServicesAmt>141062</ProgramServicesAmt>
        <ManagementAndGeneralAmt>55227</ManagementAndGeneralAmt>
        <FundraisingAmt>6916</FundraisingAmt>
      </TravelGrp>
      <PymtTravelEntrtnmntPubOfclGrp>
        <TotalAmt>0</TotalAmt>
      </PymtTravelEntrtnmntPubOfclGrp>
      <ConferencesMeetingsGrp>
        <TotalAmt>58419</TotalAmt>
        <ProgramServicesAmt>55362</ProgramServicesAmt>
        <ManagementAndGeneralAmt>3057</ManagementAndGeneralAmt>
      </ConferencesMeetingsGrp>
      <InterestGrp>
        <TotalAmt>0</TotalAmt>
      </InterestGrp>
      <PaymentsToAffiliatesGrp>
        <TotalAmt>0</TotalAmt>
      </PaymentsToAffiliatesGrp>
      <DepreciationDepletionGrp>
        <TotalAmt>29515</TotalAmt>
        <ProgramServicesAmt>21757</ProgramServicesAmt>
        <ManagementAndGeneralAmt>4743</ManagementAndGeneralAmt>
        <FundraisingAmt>3015</FundraisingAmt>
      </DepreciationDepletionGrp>
      <InsuranceGrp>
        <TotalAmt>36361</TotalAmt>
        <ProgramServicesAmt>26775</ProgramServicesAmt>
        <ManagementAndGeneralAmt>5869</ManagementAndGeneralAmt>
        <FundraisingAmt>3717</FundraisingAmt>
      </InsuranceGrp>
      <OtherExpensesGrp>
        <Desc>DIRECT MAIL PROGRAMS</Desc>
        <TotalAmt>6070245</TotalAmt>
        <ProgramServicesAmt>3948021</ProgramServicesAmt>
        <FundraisingAmt>2122224</FundraisingAmt>
      </OtherExpensesGrp>
      <OtherExpensesGrp>
        <Desc>LOCK BOX SERVICE</Desc>
        <TotalAmt>132885</TotalAmt>
        <ProgramServicesAmt>90662</ProgramServicesAmt>
        <FundraisingAmt>42223</FundraisingAmt>
      </OtherExpensesGrp>
      <OtherExpensesGrp>
        <Desc>PROCESS FEES-LIST SALES</Desc>
        <TotalAmt>61574</TotalAmt>
        <ProgramServicesAmt>41855</ProgramServicesAmt>
        <FundraisingAmt>19719</FundraisingAmt>
      </OtherExpensesGrp>
      <OtherExpensesGrp>
        <Desc>PLANNED GIVING</Desc>
        <TotalAmt>15496</TotalAmt>
        <ManagementAndGeneralAmt>15496</ManagementAndGeneralAmt>
      </OtherExpensesGrp>
      <AllOtherExpensesGrp>
        <TotalAmt>13304</TotalAmt>
        <FundraisingAmt>13304</FundraisingAmt>
      </AllOtherExpensesGrp>
      <TotalFunctionalExpensesGrp>
        <TotalAmt>13432400</TotalAmt>
        <ProgramServicesAmt>9662444</ProgramServicesAmt>
        <ManagementAndGeneralAmt>1083915</ManagementAndGeneralAmt>
        <FundraisingAmt>2686041</FundraisingAmt>
      </TotalFunctionalExpensesGrp>
      <JointCostsInd>X</JointCostsInd>
      <TotalJointCostsGrp>
        <TotalAmt>6528202</TotalAmt>
        <ProgramServicesAmt>4496015</ProgramServicesAmt>
        <FundraisingAmt>2032187</FundraisingAmt>
      </TotalJointCostsGrp>
      <CashNonInterestBearingGrp>
        <BOYAmt>1000</BOYAmt>
        <EOYAmt>1000</EOYAmt>
      </CashNonInterestBearingGrp>
      <SavingsAndTempCashInvstGrp>
        <BOYAmt>4121992</BOYAmt>
        <EOYAmt>2565486</EOYAmt>
      </SavingsAndTempCashInvstGrp>
      <PledgesAndGrantsReceivableGrp>
        <BOYAmt>0</BOYAmt>
        <EOYAmt>0</EOYAmt>
      </PledgesAndGrantsReceivableGrp>
      <AccountsReceivableGrp>
        <BOYAmt>137805</BOYAmt>
        <EOYAmt>119157</EOYAmt>
      </AccountsReceivableGrp>
      <ReceivablesFromOfficersEtcGrp>
        <BOYAmt>0</BOYAmt>
        <EOYAmt>0</EOYAmt>
      </ReceivablesFromOfficersEtcGrp>
      <RcvblFromDisqualifiedPrsnGrp>
        <BOYAmt>0</BOYAmt>
        <EOYAmt>0</EOYAmt>
      </RcvblFromDisqualifiedPrsnGrp>
      <OthNotesLoansReceivableNetGrp>
        <BOYAmt>0</BOYAmt>
        <EOYAmt>0</EOYAmt>
      </OthNotesLoansReceivableNetGrp>
      <InventoriesForSaleOrUseGrp>
        <BOYAmt>0</BOYAmt>
        <EOYAmt>0</EOYAmt>
      </InventoriesForSaleOrUseGrp>
      <PrepaidExpensesDefrdChargesGrp>
        <BOYAmt>367657</BOYAmt>
        <EOYAmt>424444</EOYAmt>
      </PrepaidExpensesDefrdChargesGrp>
      <LandBldgEquipCostOrOtherBssAmt>339846</LandBldgEquipCostOrOtherBssAmt>
      <LandBldgEquipAccumDeprecAmt>216528</LandBldgEquipAccumDeprecAmt>
      <LandBldgEquipBasisNetGrp>
        <BOYAmt>47474</BOYAmt>
        <EOYAmt>123318</EOYAmt>
      </LandBldgEquipBasisNetGrp>
      <InvestmentsPubTradedSecGrp>
        <BOYAmt>7953047</BOYAmt>
        <EOYAmt>9104342</EOYAmt>
      </InvestmentsPubTradedSecGrp>
      <InvestmentsOtherSecuritiesGrp>
        <BOYAmt>442</BOYAmt>
        <EOYAmt>442</EOYAmt>
      </InvestmentsOtherSecuritiesGrp>
      <InvestmentsProgramRelatedGrp>
        <BOYAmt>0</BOYAmt>
        <EOYAmt>0</EOYAmt>
      </InvestmentsProgramRelatedGrp>
      <IntangibleAssetsGrp>
        <BOYAmt>0</BOYAmt>
        <EOYAmt>0</EOYAmt>
      </IntangibleAssetsGrp>
      <OtherAssetsTotalGrp>
        <BOYAmt>2398467</BOYAmt>
        <EOYAmt>2611748</EOYAmt>
      </OtherAssetsTotalGrp>
      <TotalAssetsGrp>
        <BOYAmt>15027884</BOYAmt>
        <EOYAmt>14949937</EOYAmt>
      </TotalAssetsGrp>
      <AccountsPayableAccrExpnssGrp>
        <BOYAmt>2455944</BOYAmt>
        <EOYAmt>2034818</EOYAmt>
      </AccountsPayableAccrExpnssGrp>
      <GrantsPayableGrp>
        <BOYAmt>0</BOYAmt>
        <EOYAmt>0</EOYAmt>
      </GrantsPayableGrp>
      <DeferredRevenueGrp>
        <BOYAmt>18467</BOYAmt>
        <EOYAmt>8327</EOYAmt>
      </DeferredRevenueGrp>
      <TaxExemptBondLiabilitiesGrp>
        <BOYAmt>0</BOYAmt>
        <EOYAmt>0</EOYAmt>
      </TaxExemptBondLiabilitiesGrp>
      <EscrowAccountLiabilityGrp>
        <BOYAmt>0</BOYAmt>
        <EOYAmt>0</EOYAmt>
      </EscrowAccountLiabilityGrp>
      <LoansFromOfficersDirectorsGrp>
        <BOYAmt>0</BOYAmt>
        <EOYAmt>0</EOYAmt>
      </LoansFromOfficersDirectorsGrp>
      <MortgNotesPyblScrdInvstPropGrp>
        <BOYAmt>0</BOYAmt>
        <EOYAmt>0</EOYAmt>
      </MortgNotesPyblScrdInvstPropGrp>
      <UnsecuredNotesLoansPayableGrp>
        <BOYAmt>0</BOYAmt>
        <EOYAmt>0</EOYAmt>
      </UnsecuredNotesLoansPayableGrp>
      <OtherLiabilitiesGrp>
        <BOYAmt>0</BOYAmt>
        <EOYAmt>0</EOYAmt>
      </OtherLiabilitiesGrp>
      <TotalLiabilitiesGrp>
        <BOYAmt>2474411</BOYAmt>
        <EOYAmt>2043145</EOYAmt>
      </TotalLiabilitiesGrp>
      <OrganizationFollowsSFAS117Ind>X</OrganizationFollowsSFAS117Ind>
      <UnrestrictedNetAssetsGrp>
        <BOYAmt>9030911</BOYAmt>
        <EOYAmt>9308044</EOYAmt>
      </UnrestrictedNetAssetsGrp>
      <TemporarilyRstrNetAssetsGrp>
        <BOYAmt>1539542</BOYAmt>
        <EOYAmt>1433990</EOYAmt>
      </TemporarilyRstrNetAssetsGrp>
      <PermanentlyRstrNetAssetsGrp>
        <BOYAmt>1983020</BOYAmt>
        <EOYAmt>2164758</EOYAmt>
      </PermanentlyRstrNetAssetsGrp>
      <TotalNetAssetsFundBalanceGrp>
        <BOYAmt>12553473</BOYAmt>
        <EOYAmt>12906792</EOYAmt>
      </TotalNetAssetsFundBalanceGrp>
      <TotLiabNetAssetsFundBalanceGrp>
        <BOYAmt>15027884</BOYAmt>
        <EOYAmt>14949937</EOYAmt>
      </TotLiabNetAssetsFundBalanceGrp>
      <ReconcilationRevenueExpnssAmt>-473755</ReconcilationRevenueExpnssAmt>
      <NetUnrlzdGainsLossesInvstAmt>827074</NetUnrlzdGainsLossesInvstAmt>
      <MethodOfAccountingAccrualInd>X</MethodOfAccountingAccrualInd>
      <AccountantCompileOrReviewInd>false</AccountantCompileOrReviewInd>
      <FSAuditedInd>true</FSAuditedInd>
      <FSAuditedBasisGrp>
        <ConsolidatedBasisFinclStmtInd>X</ConsolidatedBasisFinclStmtInd>
      </FSAuditedBasisGrp>
      <AuditCommitteeInd>true</AuditCommitteeInd>
      <FederalGrantAuditRequiredInd>false</FederalGrantAuditRequiredInd>
    </IRS990>
    <IRS990ScheduleA documentId="IRS990ScheduleA">
      <PublicOrganization170Ind>X</PublicOrganization170Ind>
      <GiftsGrantsContriRcvd170Grp>
        <CurrentTaxYearMinus4YearsAmt>12996075</CurrentTaxYearMinus4YearsAmt>
        <CurrentTaxYearMinus3YearsAmt>14884024</CurrentTaxYearMinus3YearsAmt>
        <CurrentTaxYearMinus2YearsAmt>13729474</CurrentTaxYearMinus2YearsAmt>
        <CurrentTaxYearMinus1YearAmt>13952247</CurrentTaxYearMinus1YearAmt>
        <CurrentTaxYearAmt>11921451</CurrentTaxYearAmt>
        <TotalAmt>67483271</TotalAmt>
      </GiftsGrantsContriRcvd170Grp>
      <TaxRevLeviedOrgnztnlBnft170Grp>
        <TotalAmt>0</TotalAmt>
      </TaxRevLeviedOrgnztnlBnft170Grp>
      <GovtFurnSrvcFcltsVl170Grp>
        <TotalAmt>0</TotalAmt>
      </GovtFurnSrvcFcltsVl170Grp>
      <TotalCalendarYear170Grp>
        <CurrentTaxYearMinus4YearsAmt>12996075</CurrentTaxYearMinus4YearsAmt>
        <CurrentTaxYearMinus3YearsAmt>14884024</CurrentTaxYearMinus3YearsAmt>
        <CurrentTaxYearMinus2YearsAmt>13729474</CurrentTaxYearMinus2YearsAmt>
        <CurrentTaxYearMinus1YearAmt>13952247</CurrentTaxYearMinus1YearAmt>
        <CurrentTaxYearAmt>11921451</CurrentTaxYearAmt>
        <TotalAmt>67483271</TotalAmt>
      </TotalCalendarYear170Grp>
      <SubstantialContributorsTotAmt>491822</SubstantialContributorsTotAmt>
      <PublicSupportTotal170Amt>66991449</PublicSupportTotal170Amt>
      <GrossInvestmentIncome170Grp>
        <CurrentTaxYearMinus4YearsAmt>302464</CurrentTaxYearMinus4YearsAmt>
        <CurrentTaxYearMinus3YearsAmt>334775</CurrentTaxYearMinus3YearsAmt>
        <CurrentTaxYearMinus2YearsAmt>372780</CurrentTaxYearMinus2YearsAmt>
        <CurrentTaxYearMinus1YearAmt>287499</CurrentTaxYearMinus1YearAmt>
        <CurrentTaxYearAmt>296562</CurrentTaxYearAmt>
        <TotalAmt>1594080</TotalAmt>
      </GrossInvestmentIncome170Grp>
      <UnrelatedBusinessNetIncm170Grp>
        <CurrentTaxYearMinus4YearsAmt>6883</CurrentTaxYearMinus4YearsAmt>
        <CurrentTaxYearMinus3YearsAmt>7420</CurrentTaxYearMinus3YearsAmt>
        <CurrentTaxYearMinus2YearsAmt>16841</CurrentTaxYearMinus2YearsAmt>
        <CurrentTaxYearMinus1YearAmt>9182</CurrentTaxYearMinus1YearAmt>
        <CurrentTaxYearAmt>647</CurrentTaxYearAmt>
        <TotalAmt>40973</TotalAmt>
      </UnrelatedBusinessNetIncm170Grp>
      <OtherIncome170Grp>
        <CurrentTaxYearMinus4YearsAmt>320737</CurrentTaxYearMinus4YearsAmt>
        <CurrentTaxYearMinus3YearsAmt>363577</CurrentTaxYearMinus3YearsAmt>
        <CurrentTaxYearMinus2YearsAmt>341191</CurrentTaxYearMinus2YearsAmt>
        <CurrentTaxYearMinus1YearAmt>348604</CurrentTaxYearMinus1YearAmt>
        <CurrentTaxYearAmt>284518</CurrentTaxYearAmt>
        <TotalAmt>1658627</TotalAmt>
      </OtherIncome170Grp>
      <TotalSupportAmt>70776951</TotalSupportAmt>
      <PublicSupportCY170Pct>0.94652</PublicSupportCY170Pct>
      <PublicSupportPY170Pct>0.93903</PublicSupportPY170Pct>
      <ThirtyThrPctSuprtTestsCY170Ind>X</ThirtyThrPctSuprtTestsCY170Ind>
    </IRS990ScheduleA>
    <IRS990ScheduleB documentId="IRS990ScheduleB">
      <ContributorInformationGrp>
        <ContributorNum>RESTRICTED</ContributorNum>
        <ContributorBusinessName>
          <BusinessNameLine1>RESTRICTED</BusinessNameLine1>
        </ContributorBusinessName>
        <ContributorUSAddress>
          <AddressLine1>RESTRICTED</AddressLine1>
          <AddressLine2>RESTRICTED</AddressLine2>
          <City>RESTRICTED</City>
          <State>RESTRICTED</State>
          <ZIPCode>RESTRICTED</ZIPCode>
        </ContributorUSAddress>
        <TotalContributionsAmt>RESTRICTED</TotalContributionsAmt>
      </ContributorInformationGrp>
    </IRS990ScheduleB>
    <IRS990ScheduleD documentId="IRS990ScheduleD">
      <DonorAdvisedFundsHeldCnt>1</DonorAdvisedFundsHeldCnt>
      <DonorAdvisedFundsContriAmt>50</DonorAdvisedFundsContriAmt>
      <DonorAdvisedFundsVlEOYAmt>3040</DonorAdvisedFundsVlEOYAmt>
      <DisclosedOrgLegCtrlInd>true</DisclosedOrgLegCtrlInd>
      <DisclosedForCharitablePrpsInd>true</DisclosedForCharitablePrpsInd>
      <ArtPublicExhibitionAmountsGrp />
      <HeldWorksArtGrp />
      <CYEndwmtFundGrp>
        <BeginningYearBalanceAmt>8164316</BeginningYearBalanceAmt>
        <ContributionsAmt>3394266</ContributionsAmt>
        <InvestmentEarningsOrLossesAmt>213282</InvestmentEarningsOrLossesAmt>
        <OtherExpendituresAmt>3072762</OtherExpendituresAmt>
        <EndYearBalanceAmt>8699102</EndYearBalanceAmt>
      </CYEndwmtFundGrp>
      <CYMinus1YrEndwmtFundGrp>
        <BeginningYearBalanceAmt>7627682</BeginningYearBalanceAmt>
        <ContributionsAmt>3687809</ContributionsAmt>
        <InvestmentEarningsOrLossesAmt>22308</InvestmentEarningsOrLossesAmt>
        <OtherExpendituresAmt>3173483</OtherExpendituresAmt>
        <EndYearBalanceAmt>8164316</EndYearBalanceAmt>
      </CYMinus1YrEndwmtFundGrp>
      <CYMinus2YrEndwmtFundGrp>
        <BeginningYearBalanceAmt>7771063</BeginningYearBalanceAmt>
        <ContributionsAmt>3491261</ContributionsAmt>
        <InvestmentEarningsOrLossesAmt>-158768</InvestmentEarningsOrLossesAmt>
        <OtherExpendituresAmt>3475874</OtherExpendituresAmt>
        <EndYearBalanceAmt>7627682</EndYearBalanceAmt>
      </CYMinus2YrEndwmtFundGrp>
      <CYMinus3YrEndwmtFundGrp>
        <BeginningYearBalanceAmt>7621530</BeginningYearBalanceAmt>
        <ContributionsAmt>3324595</ContributionsAmt>
        <InvestmentEarningsOrLossesAmt>142232</InvestmentEarningsOrLossesAmt>
        <OtherExpendituresAmt>3317294</OtherExpendituresAmt>
        <EndYearBalanceAmt>7771063</EndYearBalanceAmt>
      </CYMinus3YrEndwmtFundGrp>
      <CYMinus4YrEndwmtFundGrp>
        <BeginningYearBalanceAmt>7363227</BeginningYearBalanceAmt>
        <ContributionsAmt>2824789</ContributionsAmt>
        <InvestmentEarningsOrLossesAmt>170917</InvestmentEarningsOrLossesAmt>
        <OtherExpendituresAmt>2737403</OtherExpendituresAmt>
        <EndYearBalanceAmt>7621530</EndYearBalanceAmt>
      </CYMinus4YrEndwmtFundGrp>
      <BoardDesignatedBalanceEOYPct>0.58630</BoardDesignatedBalanceEOYPct>
      <PrmnntEndowmentBalanceEOYPct>0.24890</PrmnntEndowmentBalanceEOYPct>
      <TermEndowmentBalanceEOYPct>0.16480</TermEndowmentBalanceEOYPct>
      <EndowmentsHeldUnrelatedOrgInd>false</EndowmentsHeldUnrelatedOrgInd>
      <EndowmentsHeldRelatedOrgInd>false</EndowmentsHeldRelatedOrgInd>
      <LandGrp />
      <BuildingsGrp />
      <LeaseholdImprovementsGrp>
        <OtherCostOrOtherBasisAmt>9782</OtherCostOrOtherBasisAmt>
        <DepreciationAmt>2376</DepreciationAmt>
        <BookValueAmt>7406</BookValueAmt>
      </LeaseholdImprovementsGrp>
      <EquipmentGrp>
        <OtherCostOrOtherBasisAmt>330064</OtherCostOrOtherBasisAmt>
        <DepreciationAmt>214152</DepreciationAmt>
        <BookValueAmt>115912</BookValueAmt>
      </EquipmentGrp>
      <OtherLandBuildingsGrp />
      <TotalBookValueLandBuildingsAmt>123318</TotalBookValueLandBuildingsAmt>
      <OtherAssetsOrgGrp>
        <Desc>AMOUNT HELD IN TRUST BY OTHERS</Desc>
        <BookValueAmt>2611748</BookValueAmt>
      </OtherAssetsOrgGrp>
      <TotalBookValueOtherAssetsAmt>2611748</TotalBookValueOtherAssetsAmt>
      <FederalIncomeTaxLiabilityAmt>0</FederalIncomeTaxLiabilityAmt>
      <TotalLiabilityAmt>0</TotalLiabilityAmt>
      <FootnoteTextInd>X</FootnoteTextInd>
      <TotalRevEtcAuditedFinclStmtAmt>13945314</TotalRevEtcAuditedFinclStmtAmt>
      <NetUnrealizedGainsInvstAmt>827074</NetUnrealizedGainsInvstAmt>
      <DonatedServicesAndUseFcltsAmt>20000</DonatedServicesAndUseFcltsAmt>
      <OtherRevenueAmt>139595</OtherRevenueAmt>
      <RevenueNotReportedAmt>986669</RevenueNotReportedAmt>
      <RevenueSubtotalAmt>12958645</RevenueSubtotalAmt>
      <TotalRevenuePerForm990Amt>12958645</TotalRevenuePerForm990Amt>
      <TotExpnsEtcAuditedFinclStmtAmt>13617616</TotExpnsEtcAuditedFinclStmtAmt>
      <DonatedServicesUseFcltsAmt>20000</DonatedServicesUseFcltsAmt>
      <OtherExpensesIncludedAmt>165216</OtherExpensesIncludedAmt>
      <ExpensesNotReportedAmt>185216</ExpensesNotReportedAmt>
      <ExpensesSubtotalAmt>13432400</ExpensesSubtotalAmt>
      <TotalExpensesPerForm990Amt>13432400</TotalExpensesPerForm990Amt>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>PART V, LINE 4 - INTENDED USE OF ENDOWMENT FUNDS:</FormAndLineReferenceDesc>
        <ExplanationTxt>THE PRINCIPAL ACTIVITIES OF NFCR ARE RAISING FUNDS AND FIGHTING CANCER THROUGH RESEARCH IN PREVENTION, EARLIER DIAGNOSTIC TECHNIQUES, MORE EFFECTIVE TREATMENTS AND ULTIMATELY, ACHIEVING ONE OF MEDICINES GREATEST GOALS: CURING CANCER TO SAVE LIVES. THE FOUNDATION FULFILLS THIS MISSION BY FUNDING ACROSS THE WORLD OUTSTANDING SCIENTISTS THAT PIONEER CANCER RESEARCH AND FUNDING CANCER PREVENTION EDUCATION PROGRAMS. THE DESIGNATED NET ASSETS, TEMPORARILY RESTRICTED NET ASSETS, AND PERMANENTLY RESTRICTED NET ASSETS ALL ARE INTENDED TO PROVIDE FUNDING FOR SUCH RESEARCH AND EDUCATION PROGRAMS.</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>PART X, LINE 2 - FIN 48 FOOTNOTE:</FormAndLineReferenceDesc>
        <ExplanationTxt>Accounting principles generally accepted in the United States of America require management to evaluate income tax positions taken and accrue an income tax liability if the organization has taken an uncertain position that more likely than not would not be sustained upon examination by the Internal Revenue Service. Management has evaluated the income tax positions taken and concluded that as of December 31, 2017 there are no uncertain tax positions taken or expected to be taken that would require recognition in the consolidated financial statements. The NFCR and affiliates are subject to routine audits by taxing jursidictions; however, there are currently no audits in progress for any tax periods. In addition, there have been no tax related interest or penalties for periods presented in these financial statements. Should such penalties and interest be incurred, the Foundation's policy would be to recognize them as management and general expenses.</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>PART XI, LINE 2D - OTHER REVENUES INCLUDED ON FINANCIALS, NOT FORM 990:</FormAndLineReferenceDesc>
        <ExplanationTxt>$139,595 - RELATED ORGANIZATIONS' REVENUES</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>PART XII, LINE 2D - OTHER EXPENSES INCLUDED ON FINANCIALS, NOT FORM 990:</FormAndLineReferenceDesc>
        <ExplanationTxt>$165,216 - RELATED ORGANIZATIONS' EXPENSES</ExplanationTxt>
      </SupplementalInformationDetail>
    </IRS990ScheduleD>
    <IRS990ScheduleF documentId="IRS990ScheduleF">
      <GrantRecordsMaintainedInd>true</GrantRecordsMaintainedInd>
      <AccountActivitiesOutsideUSGrp>
        <RegionTxt>Europe (Including Iceland and Greenland)</RegionTxt>
        <TypeOfActivitiesConductedTxt>Grantmaking</TypeOfActivitiesConductedTxt>
        <RegionTotalExpendituresAmt>30000</RegionTotalExpendituresAmt>
      </AccountActivitiesOutsideUSGrp>
      <AccountActivitiesOutsideUSGrp>
        <RegionTxt>East Asia and the Pacific</RegionTxt>
        <TypeOfActivitiesConductedTxt>Grantmaking</TypeOfActivitiesConductedTxt>
        <RegionTotalExpendituresAmt>5000</RegionTotalExpendituresAmt>
      </AccountActivitiesOutsideUSGrp>
      <SubtotalSpentAmt>35000</SubtotalSpentAmt>
      <TotalSpentAmt>35000</TotalSpentAmt>
      <ForeignIndividualsGrantsGrp>
        <TypeOfAssistanceTxt>RESEARCH REVIEW</TypeOfAssistanceTxt>
        <RegionTxt>Europe (Including Iceland and Greenland)</RegionTxt>
        <RecipientCnt>1</RecipientCnt>
        <CashGrantAmt>5000</CashGrantAmt>
        <MannerOfCashDisbursementTxt>CHECK</MannerOfCashDisbursementTxt>
      </ForeignIndividualsGrantsGrp>
      <ForeignIndividualsGrantsGrp>
        <TypeOfAssistanceTxt>RESEARCH REVIEW</TypeOfAssistanceTxt>
        <RegionTxt>East Asia and the Pacific</RegionTxt>
        <RecipientCnt>1</RecipientCnt>
        <CashGrantAmt>5000</CashGrantAmt>
        <MannerOfCashDisbursementTxt>CHECK</MannerOfCashDisbursementTxt>
      </ForeignIndividualsGrantsGrp>
      <ForeignIndividualsGrantsGrp>
        <TypeOfAssistanceTxt>CANCER RESEARCH REWARD</TypeOfAssistanceTxt>
        <RegionTxt>Europe (Including Iceland and Greenland)</RegionTxt>
        <RecipientCnt>1</RecipientCnt>
        <CashGrantAmt>25000</CashGrantAmt>
        <MannerOfCashDisbursementTxt>CHECK</MannerOfCashDisbursementTxt>
      </ForeignIndividualsGrantsGrp>
      <TransferToForeignCorpInd>false</TransferToForeignCorpInd>
      <InterestInForeignTrustInd>false</InterestInForeignTrustInd>
      <ForeignCorpOwnershipInd>false</ForeignCorpOwnershipInd>
      <PassiveForeignInvestmestCoInd>false</PassiveForeignInvestmestCoInd>
      <ForeignPartnershipInd>false</ForeignPartnershipInd>
      <BoycottCountriesInd>false</BoycottCountriesInd>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>PART I, LINE 2 - PROCEDURES FOR MONITORING USE OF GRANTS OUTSIDE USA:</FormAndLineReferenceDesc>
        <ExplanationTxt>GRANT AND CONTRACT RECIPIENTS ARE REQUIRED TO SUBMIT QUARTERLY EXPENDITURE REPORTS AND ANNUAL PROGRESS REPORTS TO NFCR.</ExplanationTxt>
      </SupplementalInformationDetail>
    </IRS990ScheduleF>
    <IRS990ScheduleG documentId="IRS990ScheduleG">
      <MailSolicitationsInd>X</MailSolicitationsInd>
      <EmailSolicitationsInd>X</EmailSolicitationsInd>
      <PhoneSolicitationsInd>X</PhoneSolicitationsInd>
      <InPersonSolicitationsInd>X</InPersonSolicitationsInd>
      <SolicitationOfNonGovtGrantsInd>X</SolicitationOfNonGovtGrantsInd>
      <SpecialFundraisingEventsInd>X</SpecialFundraisingEventsInd>
      <AgrmtProfFundraisingActyInd>true</AgrmtProfFundraisingActyInd>
      <FundraiserActivityInfoGrp>
        <PersonNm>MERKLE INC</PersonNm>
        <USAddress>
          <AddressLine1Txt>7001 COLUMBIA GATEWAY DR</AddressLine1Txt>
          <CityNm>COLUMBIA</CityNm>
          <StateAbbreviationCd>MD</StateAbbreviationCd>
          <ZIPCd>21046</ZIPCd>
        </USAddress>
        <ActivityTxt>DIRECT MAIL COUNSEL</ActivityTxt>
        <FundraiserControlOfFundsInd>false</FundraiserControlOfFundsInd>
        <GrossReceiptsAmt>6942253</GrossReceiptsAmt>
        <RetainedByContractorAmt>50237</RetainedByContractorAmt>
        <NetToOrganizationAmt>6892016</NetToOrganizationAmt>
      </FundraiserActivityInfoGrp>
      <TotalGrossReceiptsAmt>6942253</TotalGrossReceiptsAmt>
      <TotalRetainedByContractorsAmt>50237</TotalRetainedByContractorsAmt>
      <TotalNetToOrganizationAmt>6892016</TotalNetToOrganizationAmt>
      <LicensedStatesCd>AL</LicensedStatesCd>
      <LicensedStatesCd>AK</LicensedStatesCd>
      <LicensedStatesCd>AZ</LicensedStatesCd>
      <LicensedStatesCd>AR</LicensedStatesCd>
      <LicensedStatesCd>CA</LicensedStatesCd>
      <LicensedStatesCd>CO</LicensedStatesCd>
      <LicensedStatesCd>CT</LicensedStatesCd>
      <LicensedStatesCd>DC</LicensedStatesCd>
      <LicensedStatesCd>FL</LicensedStatesCd>
      <LicensedStatesCd>GA</LicensedStatesCd>
      <LicensedStatesCd>HI</LicensedStatesCd>
      <LicensedStatesCd>IL</LicensedStatesCd>
      <LicensedStatesCd>IN</LicensedStatesCd>
      <LicensedStatesCd>KS</LicensedStatesCd>
      <LicensedStatesCd>KY</LicensedStatesCd>
      <LicensedStatesCd>ME</LicensedStatesCd>
      <LicensedStatesCd>MD</LicensedStatesCd>
      <LicensedStatesCd>MA</LicensedStatesCd>
      <LicensedStatesCd>MI</LicensedStatesCd>
      <LicensedStatesCd>MN</LicensedStatesCd>
      <LicensedStatesCd>MO</LicensedStatesCd>
      <LicensedStatesCd>NH</LicensedStatesCd>
      <LicensedStatesCd>NJ</LicensedStatesCd>
      <LicensedStatesCd>NM</LicensedStatesCd>
      <LicensedStatesCd>NY</LicensedStatesCd>
      <LicensedStatesCd>NC</LicensedStatesCd>
      <LicensedStatesCd>ND</LicensedStatesCd>
      <LicensedStatesCd>OH</LicensedStatesCd>
      <LicensedStatesCd>OK</LicensedStatesCd>
      <LicensedStatesCd>OR</LicensedStatesCd>
      <LicensedStatesCd>PA</LicensedStatesCd>
      <LicensedStatesCd>RI</LicensedStatesCd>
      <LicensedStatesCd>SC</LicensedStatesCd>
      <LicensedStatesCd>TN</LicensedStatesCd>
      <LicensedStatesCd>UT</LicensedStatesCd>
      <LicensedStatesCd>VA</LicensedStatesCd>
      <LicensedStatesCd>WA</LicensedStatesCd>
      <LicensedStatesCd>WV</LicensedStatesCd>
      <LicensedStatesCd>WY</LicensedStatesCd>
      <FundraisingEventInformationGrp>
        <Event1Nm>DAFFODILS</Event1Nm>
        <GrossReceiptsEvent1Amt>125673</GrossReceiptsEvent1Amt>
        <CharitableContriEvent1Amt>87971</CharitableContriEvent1Amt>
        <GrossRevenueEvent1Amt>37702</GrossRevenueEvent1Amt>
        <FoodAndBeverageEvent1Amt>15652</FoodAndBeverageEvent1Amt>
        <EntertainmentEvent1Amt>3982</EntertainmentEvent1Amt>
        <OtherDirectExpensesEvent1Amt>3134</OtherDirectExpensesEvent1Amt>
        <Event2Nm>PLAY 4 THE CURE</Event2Nm>
        <GrossReceiptsEvent2Amt>215700</GrossReceiptsEvent2Amt>
        <CharitableContriEvent2Amt>215700</CharitableContriEvent2Amt>
        <OtherDirectExpensesEvent2Amt>10911</OtherDirectExpensesEvent2Amt>
        <OtherEventsTotalCnt>50</OtherEventsTotalCnt>
        <GrossReceiptsOtherEventsAmt>44091</GrossReceiptsOtherEventsAmt>
        <CharitableContriOtherEventsAmt>44091</CharitableContriOtherEventsAmt>
        <OthDirectExpnssOtherEventsAmt>15178</OthDirectExpnssOtherEventsAmt>
        <GrossReceiptsTotalAmt>385464</GrossReceiptsTotalAmt>
        <CharitableContributionsTotAmt>347762</CharitableContributionsTotAmt>
        <GrossRevenueTotalEventsAmt>37702</GrossRevenueTotalEventsAmt>
        <FoodAndBeverageTotalEventsAmt>15652</FoodAndBeverageTotalEventsAmt>
        <EntertainmentTotalEventsAmt>3982</EntertainmentTotalEventsAmt>
        <OthDirectExpnssTotalEventsAmt>29223</OthDirectExpnssTotalEventsAmt>
        <DirectExpenseSummaryEventsAmt>48857</DirectExpenseSummaryEventsAmt>
        <NetIncomeSummaryAmt>-11155</NetIncomeSummaryAmt>
      </FundraisingEventInformationGrp>
    </IRS990ScheduleG>
    <IRS990ScheduleI documentId="IRS990ScheduleI">
      <GrantRecordsMaintainedInd>true</GrantRecordsMaintainedInd>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>THE TRANSLATIONAL GENOMICS RESEARCH INSTITUTE</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>445 NORTH FIFTH ST</AddressLine1Txt>
          <AddressLine2Txt>SUITE 600</AddressLine2Txt>
          <CityNm>PHOENIX</CityNm>
          <StateAbbreviationCd>AZ</StateAbbreviationCd>
          <ZIPCd>85004</ZIPCd>
        </USAddress>
        <RecipientEIN>753065445</RecipientEIN>
        <IRCSectionDesc>501(c)(3)</IRCSectionDesc>
        <CashGrantAmt>100000</CashGrantAmt>
        <PurposeOfGrantTxt>RESEARCH CONTRACTS</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>ALBERT EINSTEIN COLLEGE OF MEDICINE</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>1300 MORRIS PARK AVE</AddressLine1Txt>
          <CityNm>BRONX</CityNm>
          <StateAbbreviationCd>NY</StateAbbreviationCd>
          <ZIPCd>10461</ZIPCd>
        </USAddress>
        <RecipientEIN>472209056</RecipientEIN>
        <IRCSectionDesc>501(c)(3)</IRCSectionDesc>
        <CashGrantAmt>132042</CashGrantAmt>
        <NonCashAssistanceAmt>47691</NonCashAssistanceAmt>
        <ValuationMethodUsedDesc>FMV</ValuationMethodUsedDesc>
        <NonCashAssistanceDesc>CHEMICALS &amp; EQUIP</NonCashAssistanceDesc>
        <PurposeOfGrantTxt>RESEARCH CONTRACTS</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>CASE WESTERN RESERVE UNIVERSITY</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>10900 EUCLID AVENUE</AddressLine1Txt>
          <CityNm>CLEVELAND</CityNm>
          <StateAbbreviationCd>OH</StateAbbreviationCd>
          <ZIPCd>44106</ZIPCd>
        </USAddress>
        <RecipientEIN>341018992</RecipientEIN>
        <IRCSectionDesc>501(c)(3)</IRCSectionDesc>
        <CashGrantAmt>137633</CashGrantAmt>
        <PurposeOfGrantTxt>RESEARCH CONTRACTS</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>DANA-FARBER CANCER INSTITUTE</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>44 BINNEY ST</AddressLine1Txt>
          <AddressLine2Txt>MAIL STOP L229</AddressLine2Txt>
          <CityNm>BOSTON</CityNm>
          <StateAbbreviationCd>MA</StateAbbreviationCd>
          <ZIPCd>02115</ZIPCd>
        </USAddress>
        <RecipientEIN>042263040</RecipientEIN>
        <IRCSectionDesc>501(c)(3)</IRCSectionDesc>
        <CashGrantAmt>49850</CashGrantAmt>
        <PurposeOfGrantTxt>RESEARCH CONTRACTS</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>MASSACHUSETTS GENERAL HOSPITAL</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>PO BOX 414876</AddressLine1Txt>
          <CityNm>BOSTON</CityNm>
          <StateAbbreviationCd>MA</StateAbbreviationCd>
          <ZIPCd>02241</ZIPCd>
        </USAddress>
        <RecipientEIN>041564655</RecipientEIN>
        <IRCSectionDesc>501(c)(3)</IRCSectionDesc>
        <CashGrantAmt>295000</CashGrantAmt>
        <NonCashAssistanceAmt>39987</NonCashAssistanceAmt>
        <ValuationMethodUsedDesc>FMV</ValuationMethodUsedDesc>
        <NonCashAssistanceDesc>CHEMICALS &amp; EQUIP</NonCashAssistanceDesc>
        <PurposeOfGrantTxt>RESEARCH CONTRACTS</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>THE SCRIPPS RESEARCH INSTITUTE</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>10550 N TORREY PINES RD</AddressLine1Txt>
          <CityNm>LA JOLLA</CityNm>
          <StateAbbreviationCd>CA</StateAbbreviationCd>
          <ZIPCd>92037</ZIPCd>
        </USAddress>
        <RecipientEIN>330435954</RecipientEIN>
        <IRCSectionDesc>501(c)(3)</IRCSectionDesc>
        <CashGrantAmt>172331</CashGrantAmt>
        <PurposeOfGrantTxt>RESEARCH CONTRACTS</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>UNIVERSITY OF TEXAS - MD ANDERSON CANCER CENTER</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>PO BOX 4390</AddressLine1Txt>
          <CityNm>HOUSTON</CityNm>
          <StateAbbreviationCd>TX</StateAbbreviationCd>
          <ZIPCd>77210</ZIPCd>
        </USAddress>
        <RecipientEIN>746001118</RecipientEIN>
        <IRCSectionDesc>501(c)(3)</IRCSectionDesc>
        <NonCashAssistanceAmt>25000</NonCashAssistanceAmt>
        <ValuationMethodUsedDesc>fmv</ValuationMethodUsedDesc>
        <NonCashAssistanceDesc>chemicals &amp; equip</NonCashAssistanceDesc>
        <PurposeOfGrantTxt>RESEARCH CONTRACTS</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>UNIVERSITY OF MARYLAND</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>220 ARCH ST</AddressLine1Txt>
          <AddressLine2Txt>OFFICE LEVEL 2</AddressLine2Txt>
          <CityNm>BALTIMORE</CityNm>
          <StateAbbreviationCd>MD</StateAbbreviationCd>
          <ZIPCd>21201</ZIPCd>
        </USAddress>
        <RecipientEIN>526002033</RecipientEIN>
        <IRCSectionDesc>501(c)(3)</IRCSectionDesc>
        <CashGrantAmt>74917</CashGrantAmt>
        <NonCashAssistanceAmt>50000</NonCashAssistanceAmt>
        <ValuationMethodUsedDesc>fmv</ValuationMethodUsedDesc>
        <NonCashAssistanceDesc>chemicals &amp; equip</NonCashAssistanceDesc>
        <PurposeOfGrantTxt>RESEARCH CONTRACTS</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>VIRGINIA COMMONWEALTH UNIVERSITY</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>PO BOX 980568</AddressLine1Txt>
          <CityNm>RICHMOND</CityNm>
          <StateAbbreviationCd>VA</StateAbbreviationCd>
          <ZIPCd>23298</ZIPCd>
        </USAddress>
        <RecipientEIN>546001758</RecipientEIN>
        <IRCSectionDesc>501(C)(3)</IRCSectionDesc>
        <CashGrantAmt>50000</CashGrantAmt>
        <NonCashAssistanceAmt>10000</NonCashAssistanceAmt>
        <ValuationMethodUsedDesc>FMV</ValuationMethodUsedDesc>
        <NonCashAssistanceDesc>CHEMICALS &amp; EQUIP</NonCashAssistanceDesc>
        <PurposeOfGrantTxt>RESEARCH CONTRACTS</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>YALE UNIVERSITY</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>PO BOX 1873</AddressLine1Txt>
          <CityNm>NEW HAVEN</CityNm>
          <StateAbbreviationCd>CT</StateAbbreviationCd>
          <ZIPCd>06508</ZIPCd>
        </USAddress>
        <RecipientEIN>060646973</RecipientEIN>
        <IRCSectionDesc>501(c)(3)</IRCSectionDesc>
        <CashGrantAmt>75061</CashGrantAmt>
        <PurposeOfGrantTxt>RESEARCH CONTRACTS</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>KUMC RESEARCH INSTITUTE INC</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>3901 RAINBOW BLVD</AddressLine1Txt>
          <AddressLine2Txt>MAIL STOP 1039</AddressLine2Txt>
          <CityNm>KANSAS CITY</CityNm>
          <StateAbbreviationCd>KS</StateAbbreviationCd>
          <ZIPCd>66103</ZIPCd>
        </USAddress>
        <RecipientEIN>481108830</RecipientEIN>
        <IRCSectionDesc>501(c)(3)</IRCSectionDesc>
        <CashGrantAmt>145289</CashGrantAmt>
        <PurposeOfGrantTxt>RESEARCH CONTRACTS</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>UNIVERSITY OF PENNSYLVANIA</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>3451 WALNUT ST</AddressLine1Txt>
          <CityNm>PHILADELPHIA</CityNm>
          <StateAbbreviationCd>PA</StateAbbreviationCd>
          <ZIPCd>19104</ZIPCd>
        </USAddress>
        <RecipientEIN>231352685</RecipientEIN>
        <IRCSectionDesc>501(C)(3)</IRCSectionDesc>
        <CashGrantAmt>50000</CashGrantAmt>
        <NonCashAssistanceAmt>15000</NonCashAssistanceAmt>
        <ValuationMethodUsedDesc>FMV</ValuationMethodUsedDesc>
        <NonCashAssistanceDesc>CHEMICALS &amp; EQUIP</NonCashAssistanceDesc>
        <PurposeOfGrantTxt>RESEARCH CONTRACTS</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>UNIVERSITY OF ARIZONA</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>1303 E UNIVERSITY BLVD</AddressLine1Txt>
          <CityNm>TUCSON</CityNm>
          <StateAbbreviationCd>AZ</StateAbbreviationCd>
          <ZIPCd>85719</ZIPCd>
        </USAddress>
        <RecipientEIN>742622689</RecipientEIN>
        <IRCSectionDesc>501(C)(3)</IRCSectionDesc>
        <CashGrantAmt>49163</CashGrantAmt>
        <PurposeOfGrantTxt>RESEARCH CONTRACTS</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>SCOTTSDALE HEALTHCARE CORP</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>8125 N HAYDEN RD</AddressLine1Txt>
          <CityNm>SCOTTSDALE</CityNm>
          <StateAbbreviationCd>AZ</StateAbbreviationCd>
          <ZIPCd>85258</ZIPCd>
        </USAddress>
        <RecipientEIN>942735850</RecipientEIN>
        <IRCSectionDesc>501(C)(3)</IRCSectionDesc>
        <CashGrantAmt>12200</CashGrantAmt>
        <PurposeOfGrantTxt>CANCER HOTLINE</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>WAKE FOREST UNIVERSITY HEALTH SCIENCES</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>MEDICAL CENTER BLVD</AddressLine1Txt>
          <CityNm>WINSTONSALEM</CityNm>
          <StateAbbreviationCd>NC</StateAbbreviationCd>
          <ZIPCd>27157</ZIPCd>
        </USAddress>
        <RecipientEIN>223849199</RecipientEIN>
        <IRCSectionDesc>501(C)(3)</IRCSectionDesc>
        <CashGrantAmt>37591</CashGrantAmt>
        <NonCashAssistanceAmt>20000</NonCashAssistanceAmt>
        <ValuationMethodUsedDesc>FMV</ValuationMethodUsedDesc>
        <NonCashAssistanceDesc>CHEMICAL &amp; EQUIP</NonCashAssistanceDesc>
        <PurposeOfGrantTxt>RESEARCH CONTRACTS</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>INVAMET THERAPEUTICS LLC</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>251 LITTLE FALLS DRIVE</AddressLine1Txt>
          <CityNm>WILMINGTON</CityNm>
          <StateAbbreviationCd>DE</StateAbbreviationCd>
          <ZIPCd>19808</ZIPCd>
        </USAddress>
        <RecipientEIN>821967545</RecipientEIN>
        <CashGrantAmt>225000</CashGrantAmt>
        <PurposeOfGrantTxt>TRANSLATIONAL</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>NONPARIEL BIOTECHNOLOGIES LLC</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>2010 CORPORATE RIDGE</AddressLine1Txt>
          <CityNm>MCLEAN</CityNm>
          <StateAbbreviationCd>VA</StateAbbreviationCd>
          <ZIPCd>22102</ZIPCd>
        </USAddress>
        <RecipientEIN>475684209</RecipientEIN>
        <CashGrantAmt>375000</CashGrantAmt>
        <PurposeOfGrantTxt>TRANSLATIONAL</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>ONCOKIDS BIOSCIENCES</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>43 KENT ST 1</AddressLine1Txt>
          <CityNm>BROOKLINE</CityNm>
          <StateAbbreviationCd>MA</StateAbbreviationCd>
          <ZIPCd>02445</ZIPCd>
        </USAddress>
        <RecipientEIN>823410836</RecipientEIN>
        <CashGrantAmt>100000</CashGrantAmt>
        <PurposeOfGrantTxt>TRANSLATIONAL</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>STROMATIS PHARMA LLC</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>225 GARLAND HILL DR</AddressLine1Txt>
          <CityNm>ATHENS</CityNm>
          <StateAbbreviationCd>GA</StateAbbreviationCd>
          <ZIPCd>30605</ZIPCd>
        </USAddress>
        <RecipientEIN>822219124</RecipientEIN>
        <CashGrantAmt>125000</CashGrantAmt>
        <PurposeOfGrantTxt>TRANSLATIONAL</PurposeOfGrantTxt>
      </RecipientTable>
      <RecipientTable>
        <RecipientBusinessName>
          <BusinessNameLine1Txt>INTERLEUKIN COMBINATORIAL THERAPIES INC</BusinessNameLine1Txt>
        </RecipientBusinessName>
        <USAddress>
          <AddressLine1Txt>251 LITTLE FALLS DRIVE</AddressLine1Txt>
          <CityNm>WILMINGTON</CityNm>
          <StateAbbreviationCd>DE</StateAbbreviationCd>
          <ZIPCd>19808</ZIPCd>
        </USAddress>
        <RecipientEIN>823395941</RecipientEIN>
        <CashGrantAmt>200000</CashGrantAmt>
        <PurposeOfGrantTxt>TRANSLATIONAL</PurposeOfGrantTxt>
      </RecipientTable>
      <Total501c3OrgCnt>15</Total501c3OrgCnt>
      <TotalOtherOrgCnt>5</TotalOtherOrgCnt>
      <GrantsOtherAsstToIndivInUSGrp>
        <GrantTypeTxt>CANCER RESEARCH</GrantTypeTxt>
        <RecipientCnt>6</RecipientCnt>
        <CashGrantAmt>95341</CashGrantAmt>
      </GrantsOtherAsstToIndivInUSGrp>
      <GrantsOtherAsstToIndivInUSGrp>
        <GrantTypeTxt>RESEARCH REVIEW</GrantTypeTxt>
        <RecipientCnt>14</RecipientCnt>
        <CashGrantAmt>65400</CashGrantAmt>
      </GrantsOtherAsstToIndivInUSGrp>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>PART I, LINE 2 - PROCEDURES FOR MONITORING USE OF GRANT FUNDS IN USA:</FormAndLineReferenceDesc>
        <ExplanationTxt>GRANT AND CONTRACT RECIPIENTS ARE REQUIRED TO SUBMIT QUARTERLY EXPENDITURE REPORTS AND ANNUAL PROGRESS REPORTS TO NFCR.</ExplanationTxt>
      </SupplementalInformationDetail>
    </IRS990ScheduleI>
    <IRS990ScheduleJ documentId="IRS990ScheduleJ">
      <CompensationCommitteeInd>X</CompensationCommitteeInd>
      <Form990OfOtherOrganizationsInd>X</Form990OfOtherOrganizationsInd>
      <CompensationSurveyInd>X</CompensationSurveyInd>
      <BoardOrCommitteeApprovalInd>X</BoardOrCommitteeApprovalInd>
      <SeverancePaymentInd>false</SeverancePaymentInd>
      <SupplementalNonqualRtrPlanInd>false</SupplementalNonqualRtrPlanInd>
      <EquityBasedCompArrngmInd>false</EquityBasedCompArrngmInd>
      <CompBasedOnRevenueOfFlngOrgInd>false</CompBasedOnRevenueOfFlngOrgInd>
      <CompBsdOnRevRelatedOrgsInd>false</CompBsdOnRevRelatedOrgsInd>
      <CompBsdNetEarnsFlngOrgInd>false</CompBsdNetEarnsFlngOrgInd>
      <CompBsdNetEarnsRltdOrgsInd>false</CompBsdNetEarnsRltdOrgsInd>
      <AnyNonFixedPaymentsInd>false</AnyNonFixedPaymentsInd>
      <InitialContractExceptionInd>false</InitialContractExceptionInd>
      <RltdOrgOfficerTrstKeyEmplGrp>
        <PersonNm>FRANKLIN C SALISBURY JR</PersonNm>
        <TitleTxt>CHIEF EXECUTIVE OFFICER</TitleTxt>
        <BaseCompensationFilingOrgAmt>310842</BaseCompensationFilingOrgAmt>
        <CompensationBasedOnRltdOrgsAmt>0</CompensationBasedOnRltdOrgsAmt>
        <OtherCompensationFilingOrgAmt>1188</OtherCompensationFilingOrgAmt>
        <OtherCompensationRltdOrgsAmt>0</OtherCompensationRltdOrgsAmt>
        <DeferredCompensationFlngOrgAmt>53000</DeferredCompensationFlngOrgAmt>
        <DeferredCompRltdOrgsAmt>0</DeferredCompRltdOrgsAmt>
        <NontaxableBenefitsFilingOrgAmt>22872</NontaxableBenefitsFilingOrgAmt>
        <NontaxableBenefitsRltdOrgsAmt>0</NontaxableBenefitsRltdOrgsAmt>
        <TotalCompensationFilingOrgAmt>387902</TotalCompensationFilingOrgAmt>
        <TotalCompensationRltdOrgsAmt>0</TotalCompensationRltdOrgsAmt>
        <CompReportPrior990FilingOrgAmt>0</CompReportPrior990FilingOrgAmt>
        <CompReportPrior990RltdOrgsAmt>0</CompReportPrior990RltdOrgsAmt>
      </RltdOrgOfficerTrstKeyEmplGrp>
      <RltdOrgOfficerTrstKeyEmplGrp>
        <PersonNm>SUJUAN BA</PersonNm>
        <TitleTxt>PRESIDENT/ COO</TitleTxt>
        <BaseCompensationFilingOrgAmt>310279</BaseCompensationFilingOrgAmt>
        <CompensationBasedOnRltdOrgsAmt>0</CompensationBasedOnRltdOrgsAmt>
        <OtherCompensationFilingOrgAmt>774</OtherCompensationFilingOrgAmt>
        <OtherCompensationRltdOrgsAmt>0</OtherCompensationRltdOrgsAmt>
        <DeferredCompensationFlngOrgAmt>53000</DeferredCompensationFlngOrgAmt>
        <DeferredCompRltdOrgsAmt>0</DeferredCompRltdOrgsAmt>
        <NontaxableBenefitsFilingOrgAmt>12163</NontaxableBenefitsFilingOrgAmt>
        <NontaxableBenefitsRltdOrgsAmt>0</NontaxableBenefitsRltdOrgsAmt>
        <TotalCompensationFilingOrgAmt>376216</TotalCompensationFilingOrgAmt>
        <TotalCompensationRltdOrgsAmt>0</TotalCompensationRltdOrgsAmt>
        <CompReportPrior990FilingOrgAmt>0</CompReportPrior990FilingOrgAmt>
        <CompReportPrior990RltdOrgsAmt>0</CompReportPrior990RltdOrgsAmt>
      </RltdOrgOfficerTrstKeyEmplGrp>
      <RltdOrgOfficerTrstKeyEmplGrp>
        <PersonNm>KWOK LEUNG</PersonNm>
        <TitleTxt>CFO/SECRETARY</TitleTxt>
        <BaseCompensationFilingOrgAmt>161556</BaseCompensationFilingOrgAmt>
        <CompensationBasedOnRltdOrgsAmt>0</CompensationBasedOnRltdOrgsAmt>
        <BonusFilingOrganizationAmount>20000</BonusFilingOrganizationAmount>
        <OtherCompensationFilingOrgAmt>774</OtherCompensationFilingOrgAmt>
        <OtherCompensationRltdOrgsAmt>0</OtherCompensationRltdOrgsAmt>
        <DeferredCompensationFlngOrgAmt>24457</DeferredCompensationFlngOrgAmt>
        <DeferredCompRltdOrgsAmt>0</DeferredCompRltdOrgsAmt>
        <NontaxableBenefitsFilingOrgAmt>2439</NontaxableBenefitsFilingOrgAmt>
        <NontaxableBenefitsRltdOrgsAmt>0</NontaxableBenefitsRltdOrgsAmt>
        <TotalCompensationFilingOrgAmt>209226</TotalCompensationFilingOrgAmt>
        <TotalCompensationRltdOrgsAmt>0</TotalCompensationRltdOrgsAmt>
        <CompReportPrior990FilingOrgAmt>0</CompReportPrior990FilingOrgAmt>
        <CompReportPrior990RltdOrgsAmt>0</CompReportPrior990RltdOrgsAmt>
      </RltdOrgOfficerTrstKeyEmplGrp>
      <RltdOrgOfficerTrstKeyEmplGrp>
        <PersonNm>YI WANG</PersonNm>
        <TitleTxt>CHIEF STRTGY OFF. - ALLIANCES</TitleTxt>
        <BaseCompensationFilingOrgAmt>194551</BaseCompensationFilingOrgAmt>
        <CompensationBasedOnRltdOrgsAmt>0</CompensationBasedOnRltdOrgsAmt>
        <OtherCompensationFilingOrgAmt>1188</OtherCompensationFilingOrgAmt>
        <OtherCompensationRltdOrgsAmt>0</OtherCompensationRltdOrgsAmt>
        <DeferredCompensationFlngOrgAmt>29270</DeferredCompensationFlngOrgAmt>
        <DeferredCompRltdOrgsAmt>0</DeferredCompRltdOrgsAmt>
        <NontaxableBenefitsFilingOrgAmt>2913</NontaxableBenefitsFilingOrgAmt>
        <NontaxableBenefitsRltdOrgsAmt>0</NontaxableBenefitsRltdOrgsAmt>
        <TotalCompensationFilingOrgAmt>227922</TotalCompensationFilingOrgAmt>
        <TotalCompensationRltdOrgsAmt>0</TotalCompensationRltdOrgsAmt>
        <CompReportPrior990FilingOrgAmt>0</CompReportPrior990FilingOrgAmt>
        <CompReportPrior990RltdOrgsAmt>0</CompReportPrior990RltdOrgsAmt>
      </RltdOrgOfficerTrstKeyEmplGrp>
      <RltdOrgOfficerTrstKeyEmplGrp>
        <PersonNm>JOSEPH M GILLMER</PersonNm>
        <TitleTxt>FRMR VP DVLPMNT (THRU 11/2017)</TitleTxt>
        <BaseCompensationFilingOrgAmt>164900</BaseCompensationFilingOrgAmt>
        <CompensationBasedOnRltdOrgsAmt>0</CompensationBasedOnRltdOrgsAmt>
        <OtherCompensationFilingOrgAmt>165</OtherCompensationFilingOrgAmt>
        <OtherCompensationRltdOrgsAmt>0</OtherCompensationRltdOrgsAmt>
        <DeferredCompensationFlngOrgAmt>11258</DeferredCompensationFlngOrgAmt>
        <DeferredCompRltdOrgsAmt>0</DeferredCompRltdOrgsAmt>
        <NontaxableBenefitsFilingOrgAmt>7749</NontaxableBenefitsFilingOrgAmt>
        <NontaxableBenefitsRltdOrgsAmt>0</NontaxableBenefitsRltdOrgsAmt>
        <TotalCompensationFilingOrgAmt>184072</TotalCompensationFilingOrgAmt>
        <TotalCompensationRltdOrgsAmt>0</TotalCompensationRltdOrgsAmt>
        <CompReportPrior990FilingOrgAmt>0</CompReportPrior990FilingOrgAmt>
        <CompReportPrior990RltdOrgsAmt>0</CompReportPrior990RltdOrgsAmt>
      </RltdOrgOfficerTrstKeyEmplGrp>
    </IRS990ScheduleJ>
    <IRS990ScheduleM documentId="IRS990ScheduleM">
      <WorksOfArtGrp />
      <ArtHistoricalTreasuresGrp />
      <ArtFractionalInterestGrp />
      <BooksAndPublicationsGrp />
      <ClothingAndHouseholdGoodsGrp />
      <CarsAndOtherVehiclesGrp />
      <BoatsAndPlanesGrp />
      <IntellectualPropertyGrp />
      <SecuritiesPubliclyTradedGrp>
        <NonCashCheckboxInd>X</NonCashCheckboxInd>
        <ContributionCnt>4</ContributionCnt>
        <NoncashContributionsRptF990Amt>28511</NoncashContributionsRptF990Amt>
        <MethodOfDeterminingRevenuesTxt>stock market value</MethodOfDeterminingRevenuesTxt>
      </SecuritiesPubliclyTradedGrp>
      <SecuritiesCloselyHeldStockGrp />
      <SecurPrtnrshpTrustIntrstsGrp />
      <SecuritiesMiscellaneousGrp />
      <QualifiedContribHistStructGrp />
      <QualifiedContribOtherGrp />
      <RealEstateResidentialGrp />
      <RealEstateCommercialGrp />
      <RealEstateOtherGrp />
      <CollectiblesGrp />
      <FoodInventoryGrp />
      <DrugsAndMedicalSuppliesGrp />
      <TaxidermyGrp />
      <HistoricalArtifactsGrp />
      <ScientificSpecimensGrp />
      <ArchaeologicalArtifactsGrp />
      <OtherNonCashContriTableGrp>
        <NonCashCheckboxInd>X</NonCashCheckboxInd>
        <Desc>CHEMICALS AND EQUIPMENT</Desc>
        <ContributionCnt>7</ContributionCnt>
        <NoncashContributionsRptF990Amt>207678</NoncashContributionsRptF990Amt>
        <MethodOfDeterminingRevenuesTxt>FMV</MethodOfDeterminingRevenuesTxt>
      </OtherNonCashContriTableGrp>
      <AnyPropertyThatMustBeHeldInd>false</AnyPropertyThatMustBeHeldInd>
      <ReviewProcessUnusualNCGiftsInd>true</ReviewProcessUnusualNCGiftsInd>
      <ThirdPartiesUsedInd>false</ThirdPartiesUsedInd>
    </IRS990ScheduleM>
    <IRS990ScheduleO documentId="IRS990ScheduleO">
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>PART III, LINE 1 - ORGANIZATION'S MISSION:</FormAndLineReferenceDesc>
        <ExplanationTxt>THE NATIONAL FOUNDATION FOR CANCER RESEARCH ("NFCR") IS A LEADING PUBLIC CHARITY DEDICATED TO FUNDING CANCER RESEARCH AND PUBLIC EDUCATION RELATING TO CANCER PREVENTION, EARLIER DIAGNOSIS, BETTER TREATMENTS AND ULTIMATELY, CURES FOR CANCER. NFCR PROMOTES AND FACILITATES COLLABORATION AMONG SCIENTISTS TO ACCELERATE THE PACE OF DISCOVERY FROM BENCH TO BEDSIDE. SINCE 1973, NFCR HAS PROVIDED MORE THAN $350 MILLION IN SUPPORT OF DISCOVERY-ORIENTED CANCER RESEARCH FOCUSED ON UNDERSTANDING HOW AND WHY CELLS BECOME CANCEROUS, AND ON PUBLIC EDUCATION RELATING TO CANCER PREVENTION, DETECTION, AND TREATMENT. NFCR SCIENTISTS ARE DISCOVERING CANCER'S MOLECULAR MYSTERIES AND TRANSLATING THEIR DISCOVERIES INTO THERAPIES THAT HOLD THE HOPE FOR CURING CANCER. NFCR IS ABOUT SAVING LIVES. NFCR-FUNDED RESEARCHERS ARE MAKING PROGRESS EVERY DAY IN THEIR PURSUIT OF CANCER CURES, AND THIS IS ONLY POSSIBLE WITH THE FINANCIAL SUPPORT OF MILLIONS OF DONORS NATIONWIDE. ONE STEP AT A TIME, WE ARE GETTING CLOSER TO OUR ULTIMATE GOAL-CURING CANCER, ALL TYPES OF CANCER. FOR MORE INFORMATION, PLEASE VISIT WWW.NFCR.ORG.</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>PART III, LINE 4A - CANCER RESEARCH PROGRM ACCOMPLISHMENTS:</FormAndLineReferenceDesc>
        <ExplanationTxt>HIGHLIGHTS OF RESEARCH ACCOMPLISHMENTS ======================================= WITH SUPPORT FROM OUR GENEROUS DONORS, NFCR-FUNDED SCIENTISTS HAVE MADE NUMEROUS REMARKABLE ADVANCES IN THE FIGHT AGAINST CANCER. THEIR RESEARCH ENCOMPASSES A WIDE VARIETY OF FIELDS, MANY OF WHICH COULD ULTIMATELY LEAD TO A CURE FOR THIS DEADLY DISEASE. BELOW ARE HIGHLIGHTS OF RESEARCH ACCOMPLISHMENTS MADE BY NFCR-FUNDED SCIENTISTS OVER THE PAST YEAR. DETECTION AND TREATMENT OF EARLY LIVER CANCER --------------------------------------------- LIVER CANCER IS A LEADING CAUSE OF CANCER DEATHS WORLDWIDE, ACCOUNTING FOR MORE THAN 600,000 DEATHS EACH YEAR. IN THE US, LIVER CANCER INCIDENCE HAS MORE THAN TRIPLED SINCE 1980. TREATMENTS FOR LIVER CANCER ARE GENERALLY INEFFECTIVE, AND ONLY ONE OUT OF EVERY FIVE PATIENTS SURVIVES 5 YEARS OR LONGER AFTER DIAGNOSIS. WHEN DETECTED EARLY, LIVER CANCER CAN STILL BE TREATED MUCH MORE EFFECTIVELY THAN LATE STAGE DISEASE; HOWEVER, CURRENTLY LESS THAN HALF OF THE PATIENTS ARE DETECTED IN EARLY STAGES. A TEAM OF NFCR-FUNDED SCIENTISTS ARE WORKING TO FILL BOTH GAPS WITH ONE SOLUTION. THE TEAM HAS DEVELOPED A NEW SENSITIVE MOLECULAR IMAGING PROBE THAT CAN DETECT EVEN A MINUTE AMOUNT OF A MOLECULE CALLED PMSA WHICH EXISTS IN THE VASCULATURE OF LIVER CANCER. THIS MAKES EARLY DETECTION OF SMALL LIVER TUMORS POSSIBLE. IN ADDITION, THE RADIOACTIVITY CARRIED BY THE PROBES CAN KILL THE CANCER CELLS AT THE SAME TIME, SUGGESTING THAT THESE PROBES COULD BECOME A POTENTIAL THERAPY FOR THIS DEADLY DISEASE. ONGOING SUCCESS OF THE WORK HOLDS PROMISE TO DEVELOPMENT OF A DUAL-FUCTION, DOUBLE-POWER PROBES THAT ARE ABLE TO BOTH DETECT AND TREAT LIVER CANCER IN ITS EARLY STAGES. JAMES BASILION PH.D CANCER MAY SPREAD WITHOUT LYMPH NODE INVOLVEMENT ------------------------------------------------ NFCR SCIENTISTS AND COLLABORATORS HAVE PROVIDED THE FIRST EVIDENCE THAT THE CENTURY OLD MODEL FOR CANCER METASTASIS-WHERE CANCER SPREADS FROM PRIMARY TUMOR, TO NEARBY LYMPH NODES, AND THEN TO OTHER ORGANS- MAY NOT APPLY IN ALL CASES. USING PATIENT'S BIOPSY TISSUE SAMPLES, THE SCIENTISTS DEVELOPED A SIMPLE TEST TO ANALYZE MUTATION-PRONE SEGMENTS IN DNA AND DETERMINE THE RELATIONSHIPS BETWEEN CANCER CELLS AT THE PRIMARY TUMOR, LYMPH NODES AND DISTANT SITE FROM THE SAME PATIENT. RESULTS SHOWED THAT FOR THE MAJORITY OF COLORECTAL CANCER PATIENTS STUDIED, DISTANT METASTASES ORIGINATED DIRECTLY FROM THE PRIMARY TUMOR WITHOUT INVOLVING THE LYMPH SYSTEM IN THE PROCESS. MORE RESEARCH IS NEEDED TO LEARN IF CLINICAL OUTCOMES ARE DIFFERENT FOR PATIENTS WITH METASTASES THROUGH LYMPH NODES OR WITHOUT LYMPH NODE INVOLVEMENT. THIS SAFE AND COST-EFFECTIVE WAY TO ANALYZE THE EVOLUTIONARY PATH OF CANCER COULD POTENTIALLY BE USED IN THE CLINIC TO HELP GUIDE CLINICAL MANAGEMENT OF PATIENTS WITH METASTATIC CANCER. RAKESH J. JAIN PH.D COMBINING GENE THERAPY WITH IMMUNOTHERAPY TO TREAT LATE STAGE PROSTATE CANCER ----------------------------------------------------------------------- ADOPTIVE CELL TRANSFER (ACT) IS A POWERFUL IMMUNOTHERAPY THAT INVOLVES COLLECTION OF A PATIENT'S OWN IMMUNE CELLS FOR CANCER TREATMENT. THIS THERAPY IS RECENTLY APPROVED FOR TREATING BLOOD CANCERS, AND NFCR SCIENTIST, DR. PAUL FISHER, IS TAKING AN INNOVATIVE APPROACH TO USE ACT FOR COMBATING LATE STAGE, METASTATIC PROSTATE CANCER. IN THIS NEW APPROACH, DOCTORS FIRST COLLECT THE IMMUNE T CELLS (A SUBSET OF LYMPHOCYTES THAT PLAY A CENTRAL ROLE IN DISEASE FIGHTING), EXPAND THEM IN NUMBERS, AND THEN ARM THE T CELLS WITH A GENE CALLED MDA-7/IL-24. DISCOVERED IN DR. FISHER'S LAB, THE MDA-7/IL-24 GENE ENCODES A POWERFUL PROTEIN ("CYTOKINE") THAT MODULATES THE HUMAN IMMUNE SYSTEM, ELIMINATES METASTATIC TUMOR CELLS AND HAS SHOWN POTENT IN PREVENTING BONE METASTASIS- A PAINFUL AND OFTEN LETHAL CONDITION FOR PROSTATE CANCER PATIENTS. ONCE INJECTED BACK INTO PROSTATE TUMORS, THE "SUPERCHARGED" T CELLS WILL HOME IN TO LOCAL AND DISTANT METASTATIC SITES, RELEASING THE CYTOKINE TO DIRECT CANCER CELL SUICIDE. IF PROVEN EFFECTIVE IN PRE-CLINICAL EXPERIMENTS, THIS COMBINATION THERAPY CAN ADVANCE QUICKLY TO CLINICAL TRIALS, GETTING ONE STEP CLOSER TO DELIVERING NEW THERAPY FOR TREATING THE DEADLY METASTATIC PROSTATE CANCER. PAUL B. FISHER, M.PH.D, PH.D ANCIENT ENZYME MAY BE A TUMOR SUPPRESOR --------------------------------------- AMINOACYL-TRNA SYNTHETASES (AARS) ARE A FAMILY OF ANCIENT EXQUISITE ENZYMES RESPONSIBLE FOR PROTEIN SYNTHESIS-A BASIC REQUIREMENT FOR ALL LIVING THINGS. IN RECENT YEARS, NFCR-FUNDED SCIENTISTS WHO ARE LEADING EXPERTS IN AARS RESEARCH HAVE DISCOVERED THAT THESE ENZYMES ALSO CARRY OTHER VITAL, YET UNEXPECTED BIOLOGICAL ROLES. FOR EXAMPLE, THEY FOUND THAT ONE AARS ENZYME, SERRS, MAY BE A NEW TUMOR SUPPRESSOR. THEIR EXPERIMENTAL DATA SHOW THAT SERRS INHIBITS C-MYC-A REGULATOR GENE THAT ITSELF IS VERY OFTEN FOUND TO BE UPREGULATED IN MANY TYPES OF CANCER. INHIBITION OF C-MYC SUBSEQUENTLY TURNS OFF THE DOWNSTREAM GENES C-MYC CONTROLS. THESE DOWNSTREAM GENES INCLUDE VEGF WHOSE FUNCTION IS REQUIRED FOR TUMOR SURVIVAL. THIS NEW ROLE OF SERRS TO SUPPRESS CANCER IS CURRENTLY UNDER CLOSE INVESTIGATION AND MAY LEAD TO POTENTIAL THERAPEUTIC APPLICATIONS. XIANG-LEI YANG, PH.D CLUES TO TREATING INDIVIDUAL PATIENTS WITH PANCREATIC CANCER ------------------------------------------------------------ PANCREATIC CANCER IS COMPOSED OF MANY CELLS - BOTH MALIGNANT AND NONMALIGNANT (INCLUDING NONMALIGNANT SUPPORTIVE "STROMAL CELLS", A PATIENT'S IMMUNE CELLS, AND OTHER PERHAPS UNIDENTIFIED CELL TYPES). KNOWING THE IDENTITY OF ALL CELLS IN A PATIENT'S TUMOR IS VERY IMPORTANT AS THEY CAN PROVIDE SIGNIFICANT CLUES AS TO HOW TO FIGHT THE CANCER. NFCR SCIENTISTS ESTABLISHED A METHOD FOR TISSUE DISSOCIATION AND SUBSEQUENT SINGLE CELL-BASED RNA SEQUENCING TO IDENTIFY THE RNA MOLECULES IN ALL TYPES OF CELLS. FIVE DOMINANT CELL TYPES WERE IDENTIFIED INCLUDING TWO TUMOR CELL POPULATIONS, IN ADDITION TO SIGNALING PATHWAYS THAT DRIVE THE TUMOR CELL POPULATIONS. MOREOVER, THESE DOMINANT CELL SUBTYPES WERE CONSISTENT WITH RESULTS FROM THE PATHOLOGICAL ASSAYS. THESE RESULTS MAY GIVE THE SCIENTISTS CLUES AS TO HOW TO TREAT AN INDIVIDUAL PATIENT. DANIEL VON HOFF, M.D. PRECISION ONCOLOGY STUDY OF RACIAL DIFFERENCES IN GENETIC ALTERATIONS IN SMOKING-RELATED CANCERS ------------------------------------------------------------------------ THE REASONS WORSE OUTCOMES EXIST FOR AFRICAN AMERICANS THAN CAUCASIANS FROM SMOKING RELATED CANCERS, SUCH AS LUNG, COLON AND BLADDER, HAVE BEEN ELUSIVE. NFCR SCIENTISTS CONDUCTED NEXT-GENERATION SEQUENCING (NGS) ANALYSIS OF NEARLY 500 CASES OF ADVANCED CANCERS. THEY DISCOVERED THAT AFRICAN AMERICANS HAVE AN INCREASED MUTATION RATE IN GENES FOR TUMOR SUPPRESSOR TP53, AND DNA DAMAGE REPAIR, AMONG OTHERS. THESE FINDINGS HAVE LED TO PLANNED CLINICAL TRIALS DESIGNED TO REDUCE CANCER HEALTH DISPARITY. THE OBJECTIVE OF PRECISION ONCOLOGY IS TO MATCH KNOWLEDGE OF GENETIC MUTATIONS WITH DRUGS THAT HAVE EFFECTIVELY TARGETED THE MUTATED PROTEINS. NFCR'S SUPPORT CONTINUES TO PIONEER ONCOLOGY-SEEKNG A CURE FOR ALL PATIENTS, FOR ALL CANCERS. WEI ZHANG, PH.D NEW INITIATIVE FOR 2017 ======================= THE NFCR RESEARCH ECOSYSTEM --------------------------- CANCER RESEARCH FOLLOWS A PATH FROM AN IDEA, THROUGH SEVERAL STAGES OF LABORATORY WORK, TO CLINICAL TRIALS THAT, WHEN SUCCESSFUL, ENDS IN FDA REGISTRATION AND APPROVAL OF A NEW TREATMENT. THE PROCESS OFTEN TAKES BETWEEN 7 AND 15 YEARS. MANY PROMISING AND INNOVATIVE DISCOVERIES STALL INSIDE LABORATORIES AT THE PRE-CLINICAL/PHASE I STAGES. RESEARCHERS REFER TO THESE STAGES AS THE "VALLEY OF DEATH"-WHERE INNOVATIVE DISCOVERIES DIE DUE TO LACK OF RESEARCH FUNDING. NFCR PROVIDES RESEARCH SUPPORT TO HELP SCIENTISTS LAUNCH NEW IDEAS AND TRASCEND THE VALLEY OF DEATH IN SEARCH OF BREAKTHROUGHS IN CANCER TREATMENTS. THIS YEAR, NFCR HAS STARTED TO EXTEND SUPPORT TO PROMISING CANCER RESEARCH PROJECTS ACROSS THE ENTIRE RESEARCH SPECTRUM. NFCR'S NEW TRANSLATIONAL SCIENCE PROGRAM, THE ADAPTIVE INNOVATIVE MEDICAL HIGH-IMPACT INITIATIVE (AIM HI), PROVIDES ENHANCED AND SUSTAINABLE SUPPORT TO BRIDGE THE GAP BETWEEN INNOVATION, EARLY STAGE CANCER RESEARCH AND THE SUCCESSFUL DEVELOPMENT OF HIGH-IMPACT ONCOLOGY DRUGS AND TREATMENTS. AIM HI FUNDING CAN PROVIDE A UNIQUE AND POWERFUL SPUR TO INNOVATION AND COLLABORATION, BOTH OF WHICH ARE CRUCIAL IN DEFEATING CANCER.</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>PART III, LINE 4B - CANCER PREVENTION EDUCATION TO THE PUBLIC:</FormAndLineReferenceDesc>
        <ExplanationTxt>NFCR PROVIDES THE PUBLIC WITH FREE PUBLICATIONS CONTAINING VALUABLE INFORMATION ON THE MOST UP-TO-DATE CANCER PREVENTIVE MEASURES, TREATMENT OPTIONS, AND DIAGNOSTIC TOOLS. OUR POWERFUL MESSAGE SENT TO TENS OF MILLIONS OF FAMIILIES AND REACHING TENS OF THOUSANDS OF INDIVIDUALS THROUGH OUR SOCIAL MEDIA CHANNELS (TWITTER AND FACEBOOK) AND THROUGH OUR BLOGS, HELPS TO ASSURE THAT FEWER OF TODAY'S HEALTHY INDIVIDUALS WILL GET CANCER AND MORE OF TODAY'S CANCER PATIENTS WILL BECOME TOMORROW'S CANCER SURVIVORS. OUR PUBLIC EDUCATION MATERIALS INCLUDE CANCER DETECTION GUIDE, A CHILDHOOD CANCER CHART, CANCER PREVENTION KITS, RECIPES FOR HEALTHY LIVING, ELECTRONIC AND PRINTED NEWSLETTERS, THE LATEST CANCER HEADLINES, AND IN-DEPTH ONLINE CANCER INFORMATION.</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>PART VI, SECTION A, LINE 2 - DIRECTORS/OFFICERS WITH FAMILY RELATIONSHIPS:</FormAndLineReferenceDesc>
        <ExplanationTxt>FRANKLIN SALISBURY, CEO, AND SUJUAN BA, PRESIDENT/COO, ARE HUSBAND AND WIFE.</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>PART VI, SECTION B, LINE 4 - CHANGES TO GOVERNING DOCUMENTS:</FormAndLineReferenceDesc>
        <ExplanationTxt>TWO RESOLUTIONS PASSED IN 2017 ============================== 1) THE NUMBER OF DIRECTORS SHALL NOT BE FEWER THAN FIVE (5) NOR GREATER THAN NINE (9). 2) ELECTRONIC COMMUNICATIONS FROM DIRECTORS SHALL BE DEEMED WRITINGS SIGNED BY DIRECTORS.</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>PART VI, SECTION B, LINE 11B - REVIEW PROCESS OF FORM 990:</FormAndLineReferenceDesc>
        <ExplanationTxt>THE NATIONAL FOUNDATION FOR CANCER RESEARCH'S PROCESS FOR REVIEWING THE FORM 990. ======================================================================== 1. FORM 990 WILL BE PREPARED AFTER ANNUAL AUDIT IS DONE. 2. THE FIRST DRAFT WILL BE REVIEWED BY THE CHIEF OPERATING OFFICER AND THE CHIEF FINANCIAL OFFICER. 3. AFTER RESOLVING ANY QUESTIONS OR UPDATES, THE REVISED DRAFT WILL BE SENT TO BOARD MEMBERS, PREFERABLY ELECTRONICALLY FOR THEIR REVIEW AND COMMENTS. 4. THE BOARD MEMBER'S COMMENTS, IF ANY, WILL BE INCORPORATED IN THE FINAL RETURN. 5. THE RETURN WILL BE FILED WITH THE IRS PRIOR TO THE DESIGNATED DUE DATE OR EXTENDED DUE DATE. 6. THE STATE VERSION WILL BE PROVIDED TO STATES FOR REGISTRATION RENEWALS AND THE PUBLIC PORTIONS OF THE RETURN WILL BE POSTED ON THE FOUNDATION'S WEBSITE. 7. IN THE OCCASION THAT THERE IS INSUFFIENT TIME PRIOR TO FILING FORM 990 TO SHARE IT WITH THE BOARD, OR THERE IS ABSENSE OF AN OPPORTUNITY FOR ANY MEANINGFUL REVIEW OF FORM 990 BY THE BOARD PRIOR TO THE FILINGS DEALINE, AN ELECTRONIC VERSION OF THE FILED RETURN WILL BE AVAILABLE FOR BOARD MEMEBER'S REVIEW AND COMMENTS AFTER SUBMISSION OF RETURN TO IRS. AN AMENDED RETURN IF NECESSARY, WILL BE FILED.</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>PART VI, SECTION B, LINE 12C - CONFLICT OF INTEREST POLICY COMPLIANCE:</FormAndLineReferenceDesc>
        <ExplanationTxt>EACH DIRECTOR, PRIOR TO TAKING HIS/HER POSITION ON THE BOARD, AND ALL PRESENT DIRECTORS SHALL SUBMIT IN WRITING TO THE CHAIRMAN OF THE BOARD A LIST OF ALL BUSINESSES OR OTHER ORGANIZATIONS OF WHICH HE/SHE IS AN OFFICER, DIRECTOR, TRUSTEE, MEMBER, OWNER SHAREHOLDER, EMPLOYEE OR AGENT, WITH WHICH THE FOUNDATION HAS, OR MIGHT REASONABLE IN THE FUTURE ENTER INTO, A RELATIONSHIP OR A TRANSACTION IN WHICH THE DIRECTOR WOULD HAVE CONFLICTING INTEREST ANNUALLY.</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>PART VI, SECTION B, LINE 15A/15B - OFFICERS COMPENSATION:</FormAndLineReferenceDesc>
        <ExplanationTxt>ON AN ANNUAL BASIS, THE BOARD WILL PERFORM A THOROUGH REVIEW TO DETERMINE SUITABLE COMPENSATION. THIS PROCESS INCLUDES ALL OF THE FOLLOWING THREE ELEMENTS. ======================================================================= 1. REVIEW AND APPROVAL BY BOARD OF DIRECTORS: THE COMPENSATION OF EACH OFFICER IS REVIEWED AND APPROVED BY THE BOARD OF DIRECTORS, PROVIDED THAT PERSONS WITH CONFLICTS OF INTEREST WITH RESPECT TO THE COMPENSATION ARRANGEMENT AT ISSUE ARE NOT INVOLVED IN THIS REVIEW AND APPROVAL. EACH OFFICER'S PERFORMANCE IS EVALUATED BASED ON HIS OR HER JOB RESPONSIBILITIES, AND INTERNAL AND EXTERNAL GOALS SET IN THE PREVIOUS YEAR. 2. REVIEW OF "COMPARABLE COMPENSATION" DATA: THE COMPENSATION OF EACH OFFICER IS REVIEWED AND APPROVED USING DATA AS TO COMPARABLE COMPENSATION FOR SIMILARLY QUALIFIED PERSONS IN FUNCTIONALLY COMPARABLE POSITIONS AT SIMILARLY SITUATED ORGANIZATIONS. COMPARABLE DATA ARE COMPILED BY THE FOUNDATION'S CHIEF FINANCIAL OFFICER AND/OR BY OUTSIDE COMPENSATION CONSULTANTS. COMPARABILITY DATA CAN INCLUDE COMPENSATION DATA FROM IRS FORM 990'S OF SIMILAR ORGANIZATIONS, PUBLISHED COMPENSATION SURVEYS, STUDIES AND GUIDES, AND OTHER SOURCES DEEMED APPROPRIATE AT THE TIME. 3. DOCUMENTATION AND RECORDKEEEPING: THERE IS CONTEMPORANEOUS DOCUMENTATION AND RECORDKEEPING WITH RESPECT TO THE DELIBERATIONS AND DECISIONS REGARDING THE COMPENSATION AGREEMENT. THE RECORD IS KEPT BY THE SECRETARY OF THE FOUNDATION.</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>PART VI, SECTION C, LINE19-AVAILABILTY OF DOCUMENTS, POLICIES, AND F/S:</FormAndLineReferenceDesc>
        <ExplanationTxt>THE FOUNDATION MAKES ITS GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC UPON REQUEST. THE FINANCIAL STATEMENTS ARE ALSO AVAILABLE ON THE FOUNDATION'S WEBSITE.</ExplanationTxt>
      </SupplementalInformationDetail>
      <SupplementalInformationDetail>
        <FormAndLineReferenceDesc>PART IX, LINE 26, JOINT COSTS ALLOCATION:</FormAndLineReferenceDesc>
        <ExplanationTxt>NFCR IS COMMITTED TO EFFICIENCY AND TRANSPARENCY. FOR MORE THAN 40 YEARS, NFCR HAS BEEN COMMUNICATING WITH SUPPORTERS, DONORS, AND PROSPECTIVE DONORS BY EMAIL, POSTAL EMAIL, PHONE AND OTHER MEANS, BOTH TO REQUEST CONTRIBUTIONS AND TO EDUCATE THE PUBLIC, THEREBY UPHOLDING NFCR'S MISSION STATEMENT (TO SUPPORT CANCER RESEARCH AND PUBLIC EDUCATION RELATING TO THE PREVENTION, EARLY DIAGNOSIS, BETTER TREATMENTS AND ULTIMATELY, A CURE FOR CANCER). THESE FREE PUBLICATIONS ARE SENT TO TENS OF MILLIONS OF FAMILIES AND INCLUDE MATERIALS SUCH AS EARLY DETECTION GUIDES, CHILDHOOD CANCER CHARTS, CANCER PREVENTION KITS AND RECIPES FOR HEALTHY LIVING. AS A RESULT, IN ACCORDANCE WITH THE FINANCIAL ACCOUNTING STANDARDS BOARD (FASB) GUIDELINES SOP 98-2 (ASC 958-720), WE ALLOCATE A PORTION OF OUR DIRECT MAIL COST TO PROGRAM SERVICES AND TO FUNDRAISING.</ExplanationTxt>
      </SupplementalInformationDetail>
    </IRS990ScheduleO>
    <IRS990ScheduleR documentId="IRS990ScheduleR">
      <IdRelatedTaxExemptOrgGrp>
        <DisregardedEntityName>
          <BusinessNameLine1Txt>DARWIN FOUNDATION</BusinessNameLine1Txt>
        </DisregardedEntityName>
        <USAddress>
          <AddressLine1Txt>5515 SECURITY LANE SUITE 1105</AddressLine1Txt>
          <CityNm>ROCKVILLE</CityNm>
          <StateAbbreviationCd>MD</StateAbbreviationCd>
          <ZIPCd>20852</ZIPCd>
        </USAddress>
        <EIN>371473821</EIN>
        <PrimaryActivitiesTxt>CANCER RESEAR</PrimaryActivitiesTxt>
        <LegalDomicileStateCd>DC</LegalDomicileStateCd>
        <ExemptCodeSectionTxt>501(C)3</ExemptCodeSectionTxt>
        <PublicCharityStatusTxt>509(A)(3)</PublicCharityStatusTxt>
        <DirectControllingEntityName>
          <BusinessNameLine1Txt>NFCR</BusinessNameLine1Txt>
        </DirectControllingEntityName>
        <ControlledOrganizationInd>true</ControlledOrganizationInd>
      </IdRelatedTaxExemptOrgGrp>
      <IdRelatedTaxExemptOrgGrp>
        <DisregardedEntityName>
          <BusinessNameLine1Txt>RESEARCH FOR A CURE</BusinessNameLine1Txt>
        </DisregardedEntityName>
        <USAddress>
          <AddressLine1Txt>5515 SECURITY LANE SUITE 1105</AddressLine1Txt>
          <CityNm>ROCKVILLE</CityNm>
          <StateAbbreviationCd>MD</StateAbbreviationCd>
          <ZIPCd>20852</ZIPCd>
        </USAddress>
        <EIN>010744146</EIN>
        <PrimaryActivitiesTxt>CANCER RESEAR</PrimaryActivitiesTxt>
        <LegalDomicileStateCd>DC</LegalDomicileStateCd>
        <ExemptCodeSectionTxt>501(C)3</ExemptCodeSectionTxt>
        <PublicCharityStatusTxt>509(A)(3)</PublicCharityStatusTxt>
        <DirectControllingEntityName>
          <BusinessNameLine1Txt>NFCR</BusinessNameLine1Txt>
        </DirectControllingEntityName>
        <ControlledOrganizationInd>true</ControlledOrganizationInd>
      </IdRelatedTaxExemptOrgGrp>
      <ReceiptOfIntAnntsRntsRyltsInd>false</ReceiptOfIntAnntsRntsRyltsInd>
      <GiftGrntOrCapContriToOthOrgInd>false</GiftGrntOrCapContriToOthOrgInd>
      <GiftGrntCapContriFromOthOrgInd>false</GiftGrntCapContriFromOthOrgInd>
      <LoansOrGuaranteesToOtherOrgInd>false</LoansOrGuaranteesToOtherOrgInd>
      <LoansOrGuaranteesFromOthOrgInd>false</LoansOrGuaranteesFromOthOrgInd>
      <DivRelatedOrganizationInd>false</DivRelatedOrganizationInd>
      <AssetSaleToOtherOrgInd>false</AssetSaleToOtherOrgInd>
      <AssetPurchaseFromOtherOrgInd>false</AssetPurchaseFromOtherOrgInd>
      <AssetExchangeInd>false</AssetExchangeInd>
      <RentalOfFacilitiesToOthOrgInd>false</RentalOfFacilitiesToOthOrgInd>
      <RentalOfFcltsFromOthOrgInd>false</RentalOfFcltsFromOthOrgInd>
      <PerformOfServicesForOthOrgInd>false</PerformOfServicesForOthOrgInd>
      <PerformOfServicesByOtherOrgInd>false</PerformOfServicesByOtherOrgInd>
      <SharingOfFacilitiesInd>true</SharingOfFacilitiesInd>
      <PaidEmployeesSharingInd>true</PaidEmployeesSharingInd>
      <ReimbursementPaidToOtherOrgInd>false</ReimbursementPaidToOtherOrgInd>
      <ReimbursementPaidByOtherOrgInd>false</ReimbursementPaidByOtherOrgInd>
      <TransferToOtherOrgInd>false</TransferToOtherOrgInd>
      <TransferFromOtherOrgInd>false</TransferFromOtherOrgInd>
    </IRS990ScheduleR>
  </ReturnData>
</Return>